Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS3839153 A
Type de publicationOctroi
Date de publication1 oct. 1974
Date de dépôt10 déc. 1971
Date de priorité28 déc. 1970
Autre référence de publicationCA964560A, CA964560A1, DE2164768A1, DE2164768B2
Numéro de publicationUS 3839153 A, US 3839153A, US-A-3839153, US3839153 A, US3839153A
InventeursA Schuurs, Weemen B Van
Cessionnaire d'origineAkzona Inc
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Process for the detection and determination of specific binding proteins and their corresponding bindable substances
US 3839153 A
Résumé
The invention relates to a process for the detection and determination of a component of the reaction between a specific binding protein and the corresponding bindable substance contacting a fluid containing one of these components with a conjugate of the bindable substance with an enzyme and of antibodies against the specific binding protein which latter component is brought in an insoluble form, if necessary, in combination with the specific binding protein, and determining the activity of the liquid or solid phase of the resulting reaction mixture.
Images(7)
Previous page
Next page
Revendications  disponible en
Description  (Le texte OCR peut contenir des erreurs.)

United States Patent 1 1 1111 3,839,153 Schuurs et al. p Oct. 1, 1974 [5 PROCESS FOR THE DETECTION AND 3,654,090 4 1972 Schuurs et al 195 1035 R DETERMINATION OF SPECIFIC BINDING OTHER PUBLICATIONS PROTEINS AND THEIR CORRESPONDING Nd l I t l K k S R h BINDABLE SUBSTANCES Ml gey e a. aroins a ymposia on esearc ethods 1n Reproductive Endocrinology, lst Sympo- [75] Inventors: Antonius I-Iermanus Wilhelmus sium, Sept. 23-25, I969 in Acta Endocrinologica, Maria SchuurS; Bflllke KlaaS Van Supplementum (Copenhagen), 142: 247-256 (1969). Weemen, both of NetherlandS Miles et al. Nature 219; 186-189 (1968).

[73] Assignee: Akzona Incorporated, Asheville,

N C Primary ExaminerAlvin E. Tanenholtz w Filed: Dec. 10,1971 Attorney, Agent, or Fzrm Hugo E eisberger [21] Appl. No.: 206,952 [57] ABSTRACT The invention relates to a process for the detection [30] Foreign Application Priority Data and determination of a component of the reaction be- Dec. 18, 1970 Netherlands 7018838 tween 3 Specific binding Protein and the correspond" ing bindable substance contacting a fluid containing 52 US. Cl. 195/1035 R, 424/12, 195/63 one of these Components with a conjugate Of the bind- 51 Int. Cl. G01n 31/14 able Substance with an enzyme and of antibodies [58] Field 01 Search 195/1035 R; 424/12; against the Specific binding protein which latter 23/230 B ponent is brought in an insoluble form, if necessary, in

combination with the specific binding protein, and de- 5 References Cited termining the activity of the liquid or solid phase of UNITED STATES PATENTS the resulting reaction mixture.

6 Claims, No Drawings PROCESS FOR THE DETECTION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES It is known that a component of the reaction between a specific binding protein and the corresponding bindable substance can be detected and determined by incubating one of the named components, labelled by a marker, in a reaction mixture which at least contains the other component, and then effecting a separation between the marked component that is and that is not bound to its binding partner, and finally determining the marker in at least one of the two fractions obtained. The distribution of the marked component over the two fractions is a measure of the amount of substance to be determined and present in the sample. Three systems can be described, in which the above method is applied.

a. antibodies as specific binding proteins, and the corresponding antigens as bindable substances. Substances which can be determined with this system are, inter alia, protein hormones and their antibodies, or virus antigens and their antibodies;

b. antibodies as specific binding proteins, and haptens as bindable substance. Here the haptens are defined as protein-free substances, which can react with antibodies, without being able to induce them. Substances which can be determined in such a system are, inter alia, steroid hormones and vitamines;

c. proteins which in the body act as receptor or transport molecules as specific binding proteins, and substances which are bound by them as bindable substances. This system is e.g., suitable for the determination of steroid hormones, but also of thyroxine and triiodothyronine, vitamine 8, intrinsic factor, and adrenocorticotropic hormone.

The most important points in the methods of determination described are the application of a marker and the separation of the marked component into a fraction which is, and a fraction which is not bound to the corresponding component.

In the methods practically used up to now only radioactive atoms have been applied as marker, e.g., 131,, 125,, l4 3 57 This method usually stands out by a high sensitivity. However, the application of this method is limited to institutes which have the required specialized apparatus available.

The separation methods can be divided as follows:

a. methods depending on the difference in physical properties between the non-bound, marked component and its complex with the binding partner, such as gelfiltration, electrophoresis, salt precipitation, and adsorption to dextran-coated charcoal;

b. the so-called solid phase methods, in which beforehand one component has already been brought into an insoluble form by cross-linking or by covalent binding or physical adsorption to a solid carrier.

c. the so-called double antibody method in which the complex formed, antigen (or hapten)-antibody, is precipitated with the help of antibodies against the antibody in the complex, which method is only known for systems in which antibodies are involved. Whilst the methods mentioned under (a) and (c) are relatively complicated to perform, those mentioned under (b) suffer from the disadvantage that as a result of bringing a reaction component in an insoluble form, its affinity for the reaction partner usually decreases. A high affinity is, however, essential for realizing a sensitive system of test.

Now a process was found for the detection and determination of a component of the reaction between a specific binding protein and the corresponding bindable substance, applying the known binding affinity of such components for one another, characterized in that use is made of a given amount of a coupling product of the combinable substance with an enzyme, and of antibodies against the specific combining protein, brought in an insoluble form, and that after the reaction the enzyme activity is determined in the liquid or solid phase of the reaction mixture, which activity is a measure of the amount of the component to be determined.

A frequent and advantageous use of this method is made when antibodies are made to act as specific binding protein and antigen or hapten as corresponding bindable substance.

In the present description the term conjugate and enzyme conjugate are used as synonyms for the coupling product of the bindable substance and the enzyme.

The bindable substance can be detected and determined by bringing together the unknown sample or a dilution series of same with a known amount of a conjugate of the substance to be determined and an enzyme, and with an amount of specific binding protein, depending on the amount of enzyme conjugate that was added. Then an amount, preferably an excess, of the insoluble-made antibodies against the specific binding protein is added, so that all the enzyme conjugate that has reacted with the binding protein is coupled via this protein to these insoluble antibodies. 1n proportion as there is more bindable substance present in the sample, less enzyme conjugate will react with the specific binding protein and ultimately get into the insoluble phase; the result is that more unbound enzyme conjugate remains in the liquid phase, which can simply be determined there.

The specific binding protein can be determined by incubating the sample or a dilution series of same with a known amount of enzyme conjugate and with an amount of the insoluble-made antibodies against the specific binding protein. The enzyme activity can only pass into the insoluble phase if the conjugate has reacted with the specific binding protein: the more specific binding protein there is in the sample, the less of bound enzyme conjugate remains in the liquid phase.

The sensitivity of the test systems described can be varied by altering the quantities of the reagents (whether or not in the same ratio). However, the amount of enzyme conjugate that can be applied is limited at the lower end by the requirement that its enzyme activity can be measured reasonably, so that the sensitivity of the test systems has a limit. The minimum measurable enzyme activity depends inter alia on the nature of the enzyme used for the coupling and on the nature of the substrate and of the incubation period of the enzyme reaction. Further the affinity of the specific binding proteins strongly influences the sensitivity of the determination. For a highly sensitive test system specific binding proteins with a higher affinity are required.

The quanitities of reagent required per determination are established empirically.

For the determination of the bindable substance the quantity of enzyme conjugate will be determined with the help of the enzyme activity; then this quantity is incubated with a dilution series of the specific binding protein to determine the required quantity of this protein. By preference a quantity of specific binding protein is chosen, which binds 50-90% of the enzyme conjugate. Finally it is checked whether the desired sensitivity has indeed been reached, by testing a dilution series of the substance under test in the system. For the determination of the specific binding protein another consideration regarding the dosage of the enzyme conjugate is its activity, which should be reasonably determinable.

The insoluble-made antibodies against the specific binding protein are preferably added in excess in the two types of determination; the dosing of same is determined in preliminary tests. The advantages of this method over the existing are:

a. working with radioisotopes can be replaced by working with enzymes. This requires considerably less laboratory facilities and apparatus, whilst the staff can be less highly qualified. Moreover, working with radioactive isotopes is highly limited because of legal regulations. Further the reagents according to the invention will keep long and the safety is increased;

b. the combination ofDouble Antibody and Solid Phase methods, for ease of reference called DASP method below, offers several advantages over the existing methods. Thus the performing of the found method, viz.: addition of insoluble-made antibodies against the specific binding protein, incubation, centrifuging and measuring, is very simple. The closing is often easier than in the solid phase methods because it suffices to add an excess of insoluble material, whereas in the solid phase methods an accurately measured amount of material has to be used. Moreover, the affinity of the binding protein for the bindable substance is not impaired by the binding to the carrier material, which can be the case in the solid phase method. A further advantage over the latter method is the rapid equilibrium adjustment of the reaction between specific binding protein and bindable substance (both in solution). A further advantage is that in the DASP method the insoluble-made antibody, called immunoadsorbent below, can be used in any system in which antibodies are used as specific binding protein, provided that these antibodies have been prepared in the same animal species. On the other hand, for each antigen or hapten to be determined with the solid phase method, the antibodies have to be made insoluble. The double antibody method is very sensitive for relatively low variations in salt concentrations, pH and the like, which makes a rigid control of the conditions necessary. Moreover, the method requires the addition of carrier y-globuline and consequently much second antibody to obtain an immune precipitate. In addition to being a simpler procedure. the DASP method, which does not require "carrier" y-globuline, thus leads to material saving. Further it be added that a double antibody-like separation applied to transport or receptor proteins is not possible. as no suitable carrier protein is available for this purpose. The method according to the invention will therefore offer a unique opportunity in this respect.

c. The method according to the present invention can easily be automatized. In principle it is possible to bring the reaction components together at once or to add them in any sequence. It was found, however, that the determination acquires a higher sensitivity if the immunoadsorbent is added after the incubation of the other components.

The reagent required for the invention, viz. the coupling product of antigen, hapten or bindable substance with an enzyme, can be prepared in a known manner. These methods can also be used to bind a hapten or a low-molecular bindable substance to an enzyme, provided that one substance possesses one or more aminogroups and the other one or more carboxyl-groups. If the latter is not the case then it is possible to introduce the desired group into the molecule to be coupled with the help of known organo-chemical processes. Methods are also known to bind amino or earboxyl-groups together, whether or not by introducing a bridge. Finally compounds as glutaric aldehyde, difluorodini trodiphenyl-sulphon and diand tri-chloro-s-triazine can often be used for the coupling in question. It can be necessary to separate the prepared enzyme conjugates from non-converted substances or from substances that have become inactive. To this end the known biochemical methods can be used, such as precipitation with organic solvents, gelfiltration, and centrifugation at a density gradient.

The choice of the enzyme which is taken up in the coupling product, is determined by a number of properties of that enzyme. It is, of course, essential that the enzyme should be resistant to the coupling with another molecule, i.e., modification of one or more aminoacid side chains. Also of great importance is the specific activity of the enzyme. As less enzyme conjugate needs to be added to reach a measurable enzyme effect, the test system grows more sensitive. Further those enzymes are to be preferred, of which the determination of the activity can be made in a simple manner. In the first place those enzymes are considered that can be determined colorimetrically, spectrophotometrically or fluorimetrically. This kind of determinations is suitable for automation, which is an additional advantage.

Colorimetrically those enzymes can be determined that catalyze a reaction in which a coloured substance appears or disappears, either in the primary or in the secundary reaction.

As enzymes considered to act as enzymatically active component in conjugates, are mentioned catalase, peroxidase, ,B-glucoronidase, ,B-D-glucosidase, B-D- galactosidase, urease, glucose oxidase, galactose oxidase, and alkaline phosphatase.

At the end of the reaction between the components and the reagents according to the invention the enzyme activity of the liquid or solid phase of the reaction mixture or of the two phases can be determined. Most simple is, however, to determine the enzyme activity of the liquid phase.

The insoluble-made antibodies against the specific binding proteins, which are also an essential reagent for the process of the invention, can also be prepared in a known way. The antibodies can be prepared by taking a purified preparation of the specific binding protein,

or of proteins which have at least partly the same antigen properties as the specific binding protein, and injecting this in a known way into another animal species than from which it was obtained. The serum of the treated animal, or the gammaglobuline fraction thereof, can be made insoluble by cross-linking with compounds such as glutaric aldehyde and chloroformic acid ethyl ester, or by binding to solid carrier particles, either physically by adsorption, or chemically by the formation of covalent bonds. As solid carriers can be considered materials such as cellulose (modified or not), agarose, cross-linked dcxtran, polystyrene and the like. Covalent binding of the antibodies to these materials can be effected with the help of substances such as carbodiimides, diand tri-chloro-striazines, glutaric aldehyde, cyanogenbromide, and e.g., by diazotation.

The advantages of the method of determination found are done full justice if an excess of insoluble antibodies is applied, so that the specific binding protein passes completely into the solid phase.

The forms in which the reagents can be used are manifold. The enzyme-conjugated component of the reaction system can be freeze-dried, or dissolved in a buffer. Also a solid carrier can be used, e.g., a strip of paper impregnated with the conjugate. This applies equally to the required specific binding proteins.

The insoluble component can be brought in the form of particles of different dimensions, such as granules, flakes, rods, or in the form of a strip of some carrier material.

For the performing of the procedure according to the invention a test pack is applied by preference. This consists mainly of:

l. a known amount of a conjugate of an antigen, hapten or low-molecular bindable substance with an enzyme,

2. a corresponding amount of specific binding protein (antibodies or transport or receptor proteins),

3. a known amount of insoluble-made antibodies directed against the specific binding protein used. The test pack can further contain the reagents required for the enzyme determinations, and also auxiliary means for conducting the test, such as test tubes, pipettes and bottles with dilution liquid. Such a test pack is suitable for the determination ofa bindable substance, but also for the determination of a specific binding protein, in which case the specific binding protein contained in the test pack need not be used.

The test packs are especially frequently and with advantage used for the detection and determination of an antigen or hapten and to this end they contain mainly:

a. a known amount of a conjugate of the antigen or hapten and an enzyme,

b. a corresponding amount of corresponding antibodies,

c. a known amount of insoluble-made antibodies directed against the antibodies used. When applying such test packs for the detection and determination of antibodies the antibodies mentioned under (b) are not required.

An important embodiment of a test pack according to the present invention is a test pack to be used for the determination of gonadotropic hormones, and particularly for the determination of HCG (Human Chorionic Gonadotropin) as a means to diagnose pregnancy already in a very early stage, which test pack consists of an ampoule, tube, bottle or other container containing as essential ingredients, in separate lyophilized layers, pre-determined amounts of:

a. a conjugate of HCG with an enzyme, e.g., HCG- peroxidase.

b. anti-HCG.

0. antibodies against anti-HCG, made insoluble.

d. possibly other ingredients like a buffer.

By adding a certain amount of urine of a possibly pregnant woman to this test kit and to incubate the urine with the components of the kit a mixture of insoluble material is formed whereas the supernatant contains the remaining soluble HCG-enzyme conjugate. The amount of the latter is dependent on the amount of HCG in the urine to be tested. By determining the enzyme activity of this remaining HCG-enzyme conjugate it can be ascertained whether the urine is coming from a pregnant woman or not.

A preferably applied method for the determination of the enzyme activity consists in contacting an indicatorpaper impregnated with enzyme reagents, e.g., in case use is made of a peroxidase, a H O -supplier like urea- H ,O and a colour-reagent like o-tolidine.

By a correct choice of the amounts of each of the reagents it will be possible to ascertain pregnancy already in a very early stage and in a simple, rapid and very reliable way to be performed even by unskilled persons.

Example 1 Determination of human (HCG) a. Preparation of HCG-HRP. 5 mg HCG and 20 mg horse radish peroxidase (HRP) were dissolved in 2 ml 0.05 M phosphate buffer of pH 6.2. After addition of 40 ,ul 25% glutaric aldehyde solution the mixture was shaken for 2 hours at room temperature. After 5 minutes centrifugation at 250 g, the liquid was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.2. The fractions of which the highest percentage enzyme activity was bound by antibodies against HCG were used in the test system.

b. Preparation of antibodies against HCG. Antibodies against HCG were induced in rabbits as described by Schuurs et al. Acta Endocr. (Kbh.) 59, 120 (1968).

c. Preparation of antibodies against rabbit-yglobuline. Rabbit-y-globuline was isolated from normal rabbit serum by precipitation with 18% w/v solid sodium sulphate. Antibodies against this were prepared by immunizing a sheep according to the following schedule:

choriongonadotrophine amount Freunds adjuvans injection manner intramuscular intramuscular intramuscular intravenous intravenous On day the sheep was bled.

d. Preparation of the immunoadsorbent [sheep-anti- (rabbit-y-globulineH cellulose. The y-globuline fraction of the sheep serum described under 1 c) was prepared by precipitation with 16% w/v solid sodium sulphate. After washing, the precipitate was taken up in so much 0.05 M borate buffer of pH 8.6 that the resulting protein concentration amounted to 10 mg/ml. 350 mg m-aminobenzyloxymethylcellulose was suspended in 50 ml distilled water, and diazotized by adding 10 ml 36% hydrochloric acid and, dropwise, 10 ml 10% NaNO- solution at C. The suspension was centrifuged, washed and the precipitate re-suspended in 43 ml 0.05 M sodium borate of pH 8.6. Then 7 ml of the prepared y-globuline solution was added. The mixture was stirred for 26 hours at 4C, then centrifuged and washed with 0.02 M phosphate buffer of pH 6.0.

e. Determination of HCG. A dilution series (32-16-8-4-2-1-05-0 lU/ml) of HCG in 0.02 M phosphate buffer with pH 6.0 was prepared, which contained 2% v/v normal sheep serum. 0.5 ml of each of the HCG-containing samples was incubated with 0.1 ml rabbit-(anti-HCG) serum and 0.1 ml HCG-HRP conjugate, both in suitable dilution, for half an hour at room temperature. Then 0.3 ml of the immunoadsorbent 10 mg/ml) prepared acccording to d) was added, and the resulting mixture was rotated at room temperature for 1 hour. After centrifugation the enzyme activity in the supernatant was measured by mixing 0.5 ml of this liquid with 1.5 ml substrate (10 a1 30% H 0 and mg S-aminosalicylic acid in 150 ml 0.02 M phosphate buffer of pH 6.0) and after 30 minutes at C measuring the extinction at 460 nm. In this way it proved possible to detect a HCG concentration from 0.5 to 1 lU/ml in the sample. With this method also urine samples could be tested; the test is therefore suitable for a pregnancy check. The correlation with an existing method of test, a haemagglutination inhibiting test, was good. It proved possible to raise the sensitivity of the system by the application ofa pro-incubation. Here, first the sample only was incubated with the antiserum, and

then the HCG-HRP conjugate was added.

Example 11 Determination of insuline and anti-insuline.

a. Preparation of insuline-(glucose oxidase). 5 mg pig insuline and 25 mg glucose oxidase were dissolved in 2 ml 0.05 M phosphate buffer of pH 6.5. To this, 5 ,ul 25% glutaric aldehyde solution was added, after which the mixture was shaken for 90 minutes at room temperature. The mixture was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.5. The fractions of which the highest percentage of enzyme activity could be bound by antibodies against insuline, were used in the test system.

b. Preparation of antibodies against insuline. 1O

guinea pigs were given a weekly intramuscular injection with 1 mg pig insuline in complete Freunds adjuvans over a period from 4-8 weeks. After two weeks rest the animals were given 1 mg additional insuline by intravenous injection without adjuvans. 2 weeks after that the animals were bled. Hypoglycaemia occurring at times was counteracted by intraperitoneal administration of glucose.

0. Preparation of antibodies against guinea pig y-globuline. Guinea pig y-globuline was prepared by adding 1 volume saturated ammonium sulphate solution to 2 volumes guinea pig serum. The precipitate formed was twice washed with 33% saturated ammonium sulphate solution, and then taken up in a physiological salt solution. A sheep was immunized with increasing doses of the prepared 'y-globuline: 0.5, 1 and 2 mg. The injections were given every two weeks, whilst the immunogen was mixed with complete Freunds adjuvans. Two weeks after the last injection an additional 2 mg y-globuline in a physiological salt solution were given, and 1 week later the animal was bled.

d. Preparation of insoluble antibodies against guinea pig y-globuline. 10 g microcrystalline cellulose was activated by adding it whilst stirring to 400 ml 2.5% w/v CNBr-solution, after which the pH was brought to 10.5 with 1 N NaOH solution and maintained thus for 2 minutes. Then the cellulose was washed with ice water and with 0.1 M NaHCO;,. To 10 ml sheep-anti( guinea pig y-globuline) serum 1.6 g

Na SO was added. After 1 hour stirring at room temperature the precipitate was centrifuged, twice washed with 20 ml 16% w/v Na SO solution, and subsequently taken up in 10 ml 0.1 M NaHCO;,. The activated cellulose was mixed with 40 ml 0.1 M NaHCO;, solution and the 10 ml y-globuline solution. This suspension was rotated for 40 hours at 4C, and in succession washed with twice 500 ml 0.5 M NaHCO;; twice 500 ml 0.05 M citrate pH 1.1, and twice 500 ml 0.05 M phosphate of pH 6.2.

e. Determination of antibodies against insu1ine. 0.1

ml insuline-(glucose oxidase), in a suitable dilution, was incubated with 0.4 m1 of a dilution series of a guinea pig anti-insuline serum for 4 hours. The dilution series was made with 0.05 M phosphate buffer of pH 6.0. Then 0.3 ml immunoadsorbent (15 mg/ml) and 0.2 ml buffer were added and the mixture was rotated during the night at 4C. After centrifuging the enzyme activity of the supernatant was determined by incubating 0.5 ml of same with 2.5 ml substrate for 30 minutes, and then measuring the extinction at 460 nm. The substrate con tained 50 mg glucose, 10 ug peroxidase and 1 mg S-aminosalicyclic acid per 2.5 ml 0.05 M phosphate buffer of pH 6.0. By means of this system the antibody content of the different serums could be intercompared. As reference point was chosen the serum dilution at which 50% of the total combinable enzyme activity is bound.

f. Determination of insuline. 0.2 ml of a dilution series of insuline was incubated for 2 hours with 0.4 ml anti-insuline serum in such a dilution that it could bind 60% of the enzyme conjugate to be added. Then 0.1 ml insuline-(glucose oxidase) was added in the corresponding dilution, and incubated for 4 hours. Finally 0.3 ml immunoadsorbent (15 mg/ml) was added. The mixture was rotated during the night at 4C. After centrifuging the enzyme activity of the supernatant was measured as described under (e). The sensitivity of the determination, which depends on the antiserum used, lies in the nanogram range: 20-100 ng/ml, i.e., 0.5-2.5 mU/ml.

Example 11] Determination of oestradiol.

a. Preparation of oestradiol-17-succinyl-HRP. 50 mg oestradiol-17-hemisuccinate and 0.08 ml tri-nbutylamine were dissolved in 2.5 ml dioxane. To the cold (2C) solution 15 pl isobutylchlorocarbonate was added. After 30 minutes this solution was mixed with 100 mg horse radish peroxidase (HRP) in 7.5 ml of a dioxanc/water mixture (2:3) which had been adjusted to pH 9.5 with sodium hydroxide. The solution was stirred for 4 hours at 2C, and then dialyzed for 18 hours. The precipitate formed after the pH of the dialysate had been adjusted to 4.6, was centrifuged, washed and taken up in 5 ml distilled water that had been adjusted to pH 8. The material was further purified by twice precipitating with ml acetone. The finished product was taken up in 10 ml 0.05 M phosphate buffer of pH 7.8.

b. Preparation of oestradiol-l7-succinyl-BSA. The

(1. Preparation of antibodies preparation was prepared according to the mixed anhydride method, as described in Example llla. This preparation was made starting from 100 mg oestradiol-l7-hemisuccinate and 150 mg bovine serum albumine (BSA).

. Preparation of antibodies against oestradiol. A

sheep was injected once in four weeks with 4 mg oestradiol-l7-succinyl-BSA in complete Freunds adjuvans. At regular intervals blood was taken from the sheep. The serum was absorbed with BSA that was made insoluble.

against sheep-yglobuline. Sheep-y-globuline was prepared as described in example I, but now with 16% w/v sodium sulphate. Rabbits were immunized with this sheepy-globuline according to the following schedule:

day amount Freunds adjuvans injection manner 0 200 .1g intramuscular 14 400 .1g intramuscular 28 800 g intramuscular 42 800 ig intravenous 2 weeks after the last injection the animals were bled.

e. Preparation of the immunoadsorbent [rabbit-anti(- sheep-y-globuline)l-cellulose. The y-globuline fraction of the antiscrums, described under (d), was prepared by precipitation with 18% w/v Na S0,. The product obtained was coupled to cellulose according to the Gurvich method, described in example 1.

. Determination of oestradiol. The immune reaction was made in 0.02 M phosphate buffer of pH 6.0, which contained 2% BSA: 0.5 ml sample was mixed .with 0.1 ml of the sheep-anti-oestradiol serum in the quality of the oestradiol-17-succinyl-HRP used. With a dilution of 1:12.800 of the antiserum an oestradiol concentration of 10 ng/ml could be detected in the sample. Oestriol and oestron showed a cross reaction in this system.

Example lV Determination of cortisol and corticoid-binding globuline.

a. Preparation of cortisol-2l-(galactose oxidase). 50

mg cortisol-2l-hemisuccinate and mg galatose oxidase were coupled by means of the mixed anhydride technique, as described in example llla.

b. Corticoid-binding globuline (CBG) was isolated from the serum of men by means of chromatography in succession over DEAE-cellulose and hydroxyl apatite. Antibodies against this were prepared by injecting rabbits at 14-day intervals with 500 ug CBG in complete Freunds adjuvans. After 3 months the animals were injected with 1 mg CBG and 2 weeks later they were bled.

c. The y-globuline fraction of anti-CBG serum was coupled to m-aminobenzyloxymethylcellulose, as described in example lll.

d. Determination of cortisol. 0.5 ml of a cortisolcontaining sample (standard solution) was extracted with 2 X 3 ml methylenechloride. The combined extraction liquids were evaporated to dryness. The residue was taken up in 0.5 ml 0.05 M phosphate buffer of pH 6.2, then mixed with 0.1 ml of a solution of CBG in the same buffer in a suitable concentration, and incubated for 30 minutes at 4C. Then 0.1 ml cortisol-Zl-(galactose oxidase), also in a suitable dilution, and 0.3 ml of the immunoadsorbent prepared under (0) with a concentration of 5 mg/ml were added. The mixture obtained was rotated for 2 hours at 4C and then centrifuged, after which the enzyme activity was measured in the supernatant. To this end 0.5 ml of same was added to 1.5 ml substrate consisting of 100 mg D-galactose, 20 mg 5-aminosalicyclic acid and 10 pg peroxidase in ml 0.02 M phosphate buffer of pH 6.0. After 30 minutes the extinction was measured at 460 nm. When applying 21 CBG concentration of 0.4 ig/ml and so much cortisol- 21-( galactose oxidase) that without the addition of steroids 80% of the enzyme conjugate was bound to the immunoadsorbent, it proved possible to determine amounts from 3-30 ng cortisol.

e. Determination of CBG was also possible with the reagents described. From a dilution series of transcortine, ranging from 0-1280 ng/ml, 0.5 ml was incubated for 15 minutes with 0.2 ml cortisol-21- (galactose oxidase) in a suitable dilution. Then 0.3 ml immunoadsorbent suspension (5 mg/ml) was added, and the mixture rotated for 15 minutes. The two incubations were conducted at 4C. Then the enzyme activity in the supernatant was measured as under d). The sensitivity of the test system proved to be 50 ng/ml.

Example V In a bottle the following reagents were subsequently 65 lyophilized in separate layers:

1. 0.3 ml of the immunoadsorbent suspension (10 mg/ml) as described in Example 1 a).

2. 0.1 ml of a 1% mannitol solution.

3. 0.l ml of HCG-HRP as described in Example I (a).

4. a second layer of 0.1 ml of a 1% mannitol solution.

5. 0.1 ml of rabbit (anti-HCG) serum described in Example I (b).

To this lyophilized mixture 0.5 ml of a urine sample and subsequently 0.5 ml distilled water was added. After minutes the enzyme activity in the supernatant was measured by means of a slip of paper impregnated with urea-hydrogenperoxide and o-tolidine.

If the urine sample was coming from a pregnant woman 2 lU l-lCG/ml) a blue colour appeared within 5 minutes, whereas in case of urine of a nonpregnant woman no discoloration took place within the same period.

We claim:

1. Process for the detection and determination of a bindable substance selected from the group consisting of an antigen and a hapten, comprising the steps of:

a. providing a given quantity of a conjugate of said bindable substance with an enzyme;

b. providing a corresponding given quantity of an antibody against said bindable substance;

c. admixing a sample of a fluid containing the bindable substance to be determined with the reactants of steps (a) and (b) to form a reaction mixture and allowing the reaction to go to completion;

d. separating the resulting mixture into a liquid phase and a solid phase by adding an insolubilized antibody against the antibody of step (b); and

e. determining the quantity of the bindable substance from the measure of enzyme activity of either separated phase.

2. The process of claim 1 in which the bindable substance is determined by first adding thereto the antibody, then the enzyme conjugate, and finally the insoluble antibody against the antibody.

3. Process for the detection and determination of an antibody in a fluid sample containing the same utilizing the reaction between said antibody and a bindable substance selected from the group consisting of an antigen and a hapten having an affinity therefor, comprising the steps of:

a. providing a given quantity of a conjugate of said bindable substance and an enzyme;

b. providing a given quantity of an insolubilized antibody against the antibody to be determined;

0. admixing said given quantities of steps (a) and (b) with said sample, and allowing the components to react;

d. separating the reaction mixture into a liquid phase and a solid phase; and e. determining the quantity of the antibody from the measure of enzyme activity of either separated 5 phase.

4. A test pack for the detection and determination of a bindable substance selected from the group consisting of an antigen and a hapten in a fluid sample, comprising:

a. a known amount of a conjugate of said bindable substance with an enzyme; b. a corresponding known amount of an antibody against said antigen or hapten; c. a known amount of an insolubilized antibody 15 against said antibody; d. a stabilizer; and e. a substrate for the determination of the enzyme activity and thus of the quantity of the antigen or hapten to be determined.

5. A test pack for the detection and determination of an antibody in a fluid sample, utilizing the reaction between said antibody and an antigen or hapten to said antibody, comprising:

a. a known amount of a conjugate of the antigen or hapten with an enzyme;

b. a corresponding known amount of an insolubilized antibody against the antibody to be determined;

c. a stabilizer; and 3 d. a substrate for the determination of the enzyme activity and thus of the quantity of antibody to be determined.

6. A test pack for the determination of pregnancy by the detection and determination of human chorionic gonadotropin in a sample of urine, utilizing the reaction between human chorionic gonadotropin-and an antibody therefor, comprising, in separate lyophilized layers:

a. a predetermined amount of a conjugate of human chorionic gonadotropin and an enzyme;

b. a predetermined amount of an antibody against human chorionic gonadotropin;

c. a predetermined amount of an antibody against the human chorionic gonadotropin antibody, in insolubilized form;

d. a stabilizer; and

e. a substrate for the determination of the enzyme activity and thus of the quantity of human chorionic gonadotropin enzyme conjugate and human chorionic gonadotropin to be determined.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US3652761 *4 sept. 196928 mars 1972Corning Glass WorksImmunochemical composites and antigen or antibody purification therewith
US3654090 *24 sept. 196820 juil. 1982 Titre non disponible
Citations hors brevets
Référence
1 *Miles et al. Nature 219: 186 189 (1968).
2 *Nidgley et al. Karolinska Symposia on Research Methods in Reproductive Endocrinology, 1st Symposium, Sept. 23 25, 1969 in Acta Endocrinologica, Supplementum (Copenhagen), 142: 247 256 (1969).
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US3935074 *17 déc. 197327 janv. 1976Syva CompanyAntibody steric hindrance immunoassay with two antibodies
US4001087 *5 nov. 19754 janv. 1977The United States Of AmericaAffinity labelling enzymes with esters of aromatic sulfonic acids
US4002532 *21 oct. 197411 janv. 1977Weltman Joel KEnzyme conjugates
US4040907 *29 déc. 19759 août 1977Syva CompanyIodothyronine enzyme conjugates
US4045384 *23 juil. 197630 août 1977The Dow Chemical CompanyMethod for forming an amide bond between a latex and protein
US4162003 *16 mars 197824 juil. 1979Dezso Istvan BartosReady-for-use rapid test package for serological tests
US4200508 *9 févr. 197829 avr. 1980Hidematsu HiraiMethod and composition for detecting antigenic substances
US4200690 *14 juil. 197829 avr. 1980Millipore CorporationImmunoassay with membrane immobilized antibody
US4230797 *10 avr. 197828 oct. 1980Miles Laboratories, Inc.Heterogenous specific binding assay employing a coenzyme as label
US4239746 *13 avr. 197916 déc. 1980Dezso Istvan BartosComplement fixation test employing reactants in a disposable package
US4260678 *23 févr. 19797 avr. 1981Corning Glass WorksDetermining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes
US4289748 *31 mai 197915 sept. 1981United States Of AmericaUltrasensitive enzymatic radioimmunoassay method
US4298685 *3 mai 19793 nov. 1981Burroughs Wellcome Co.Diagnostic reagent
US4298687 *16 oct. 19793 nov. 1981Roland MaesProcess for the determination of compounds showing among themselves specific binding affinities by the use of a solid phase
US4318980 *15 oct. 19799 mars 1982Miles Laboratories, Inc.Heterogenous specific binding assay employing a cycling reactant as label
US4322495 *11 mars 198030 mars 1982Minnesota Mining And Manufacturing Co.Immunoassay
US4323647 *15 oct. 19806 avr. 1982University Of MiamiSteric hindrance enzyme immunoassay
US4343896 *1 mai 198010 août 1982Akzona IncorporatedMethod and test pack for the demonstration and determination of an antigen or antibody
US4347311 *2 juil. 198031 août 1982MEDAC Gesellschaft fur Klinishce Spezialpraparate mbHEnzyme immunoassay for determining antigen specific antibodies and test kit for carrying out this assay
US4350761 *15 mai 198021 sept. 1982Yamasu Shoyu Kabushiki KaishaMethod of and reagents for quantitative analysis of cyclic nucleotides
US4394391 *19 févr. 198019 juil. 1983Thorell Jan IvanRadioimmunoassay reagents
US4407943 *13 mars 19804 oct. 1983Millipore CorporationImmobilized antibody or antigen for immunoassay
US4443365 *24 juin 198117 avr. 1984Dainippon Pharmaceutical Company LimitedMethod for determination of the valproic acid and reagents therein
US4469796 *5 mai 19814 sept. 1984Pharmacia Diagnostics AbAssaying methods involving biospecific affinity reactions
US4474878 *29 sept. 19752 oct. 1984Cordis Laboratories, Inc.Sandwich EIA for antigen associated with hepatitis
US4492751 *15 oct. 19798 janv. 1985Miles Laboratories, Inc.Heterogenous specific binding assay employing an enzyme substrate as label
US4506009 *30 mars 198219 mars 1985University Of CaliforniaHeterogeneous immunoassay method
US4515890 *8 nov. 19827 mai 1985Abbott LaboratoriesImmunoassay of terminal deoxynucleotidyl transferase
US4535057 *26 juil. 198213 août 1985Amf IncorporatedImmunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4604365 *28 mai 19825 août 1986Electro-Nucleonics, Inc.Immunoprecipitation assay
US4629688 *10 avr. 197816 déc. 1986Miles Laboratories, Inc.Homogeneous specific binding assay method
US4642285 *2 mai 198410 févr. 1987Diamedix CorporationSandwich EIA for antigen
US4778752 *17 déc. 198618 oct. 1988Scripps Clinic And Research FoundationReceptors specific for hapten-modified self proteins
US4937199 *17 mars 198626 juin 1990The Royal Free Hospital School Of MedicineDetection of viruses and antibodies
US4956303 *28 avr. 198711 sept. 1990Antibody Technology LimitedSecondary antibodies against complexes of small molecules and binding partners therefor, their preparation, and their use in diagnostic methods
US5256372 *5 déc. 198926 oct. 1993Idexx CorporationDipstick test device including a removable filter assembly
US5587294 *28 oct. 199424 déc. 1996Assay Research, Inc.Method and kit for measuring endogenous cytokines
US5605800 *6 juin 199525 févr. 1997Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5607565 *27 mars 19954 mars 1997Coulter CorporationApparatus for measuring analytes in a fluid sample
US5614504 *21 avr. 199525 mars 1997The University Of South FloridaMethod of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5637467 *29 mars 199510 juin 1997Behringwerke AgHeterogeneous assay using a pendulous drop
US5728807 *21 juin 199517 mars 1998Ramot-University Authority For Applied Research And Industrial Development, Ltd.Mutated proteins associated with ataxia-telangiectasia
US5777093 *28 juil. 19957 juil. 1998Ramot-University Authority For Applied Research & Industrial Development Ltd.cDNAs associated with ataxia-telangiectasia
US5837535 *15 févr. 199617 nov. 1998Henry Ford Health SystemNeuronal-neonatal gene: neuronatin
US5840322 *19 déc. 199624 nov. 1998Ramot-University Authority For Applied Research & Industrial Devel. Ltd.Anti-oral-microbial adhesion fraction derived from vaccinium
US5843673 *7 juin 19951 déc. 1998Curators Of The University Of MissouriMethod of screening for endometriosis
US5858661 *8 avr. 199612 janv. 1999Ramot-University Authority For Applied Research And Industrial DevelopmentAtaxia-telangiectasia gene and its genomic organization
US5874423 *12 sept. 199623 févr. 1999Yissum Research Development Co. Of The Hebrew University Of JerusalemDigitalis-like compounds
US5876928 *6 juin 19952 mars 1999Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5955262 *8 sept. 199221 sept. 1999Institut PasteurMethod of detecting and characterizing a nucleic acid or reactant for the application of this method
US5965379 *28 oct. 199712 oct. 1999Cytimmune Sciences Inc.Method for measuring endogenous cytokines
US6096508 *16 août 19951 août 2000Kirkegaard & Perry Laboratoies, Inc.Method of reducing background in biotin-based assays
US61875634 août 199913 févr. 2001Yale UniversityβIV-spectrin-polypeptides and nucleic acids encoding same
US62007493 mai 199613 mars 2001Ramot-University Authority For Applied Research And Industrial Development Ltd.Mutated forms of the ataxia-telangiectasia gene and method to screen for a partial A-T phenotype
US62844962 janv. 19984 sept. 2001University Of South FloridaDNA vector for determining the presence of out-of-reading-frame mutations
US63444438 juil. 19995 févr. 2002University Of South FloridaPeptide antagonists of tumor necrosis factor alpha
US6440682 *24 mai 200027 août 2002Detroit R&D Inc.Detection of hypertension using immunoreactive metabolic products
US648238916 oct. 199819 nov. 2002University Of South FloridaMethod to diagnose and monitor cellular immune deficiencies
US6528292 *6 juin 19954 mars 2003Aventis Pharmaceuticals Holdings Inc.Derivatized polystyrene and other polymer supports for spectroscopic studies
US653127719 mars 199811 mars 2003The Curators Of The University Of MissouriEndometriosis-specific secretory protein
US655566728 juin 200029 avr. 2003Quark Biotech, Inc.Hypoxia-regulated genes
US674073823 déc. 200225 mai 2004Quark Biotech, Inc.Antibody against hypoxia proteins
US67706228 juin 20013 août 2004Gary A. JarvisN-terminally truncated galectin-3 for use in treating cancer
US67873181 juin 20007 sept. 2004Roskamp Research Institute, LlcAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US687558218 août 20005 avr. 2005Omniscience Pharmaceuticals, Inc.Methods and targets of antibiotic resistance
US699217613 févr. 200231 janv. 2006Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US69982324 avr. 200114 févr. 2006Quark Biotech, Inc.Methods of diagnosing bladder cancer
US708739516 janv. 20018 août 2006Quest Diagnostics Investments IncorporatedVitamin D assay
US710183929 août 20005 sept. 2006Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US71381449 sept. 200221 nov. 2006Nadir AskenasyMethod of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
US722390215 nov. 200029 mai 2007Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US727081028 déc. 200018 sept. 2007Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US72947012 avr. 200313 nov. 2007Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US73550795 avr. 20058 avr. 2008The Regents Of The University Of CaliforniaThyronamine derivatives and analogs and methods of use thereof
US738510610 janv. 200110 juin 2008Ramot At Tel Aviv University Ltd.Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US742313920 janv. 20049 sept. 2008Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US744278115 août 200228 oct. 2008Urifer Ltd.Diagnosis, prevention and treatment of cancer
US749842820 juin 20043 mars 2009Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US753460517 mai 200519 mai 2009Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US753460911 avr. 200519 mai 2009Pluristem Life Systems Inc.Method of expanding undifferentiated hemopoietic stem cells
US75539401 févr. 200730 juin 2009Modigene IncLong-acting EPO polypeptides and derivatives thereof and methods thereof
US75539411 févr. 200730 juin 2009Modigene IncLong-acting polypeptides and methods of producing same
US755400722 nov. 200530 juin 2009Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US760514913 juil. 199920 oct. 2009University Of South FloridaModulation of the phospholipase A2 pathway as a therapeutic
US761172320 mars 20033 nov. 2009Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US762570727 sept. 20041 déc. 2009Ramot At Tel Aviv University Ltd.Antibacterial agents and methods of identifying and utilizing same
US763252210 janv. 200615 déc. 2009Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US76329239 mars 200515 déc. 2009Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US763812425 mars 200429 déc. 2009Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US765522519 févr. 20082 févr. 2010Gamida Cell, Ltd.Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US767857311 avr. 200516 mars 2010Pluristem Ltd.Method of preparing a conditioned medium from a confluent stromal cell culture
US768705717 déc. 200230 mars 2010Yissum Research Development Company Of The Hebrew University Of JerusalemIn vitro micro-organs, and uses related thereto
US769592717 mars 200613 avr. 2010Detroit R & DDetection of hypertension using glucuronidated metabolic products
US771877718 oct. 200618 mai 2010Technion Research & Development Foundation Ltd.MHC-peptide complex binding ligands
US778139621 juin 200624 août 2010Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated disease
US778140211 oct. 200524 août 2010Closed Loop Therapies Ltd.Methods and implantable devices for treating supraventricular arrhythmias
US779067312 juin 20067 sept. 2010New York UniversityMethods and compositions relating to cystatin C
US781198129 sept. 200412 oct. 2010Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US785507519 mai 200821 déc. 2010Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US789324025 juil. 200822 févr. 2011Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US791080015 août 200622 mars 2011Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US792808316 janv. 200819 avr. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemH19 silencing nucleic acid agents for treating rheumatoid arthritis
US794749930 nov. 200324 mai 2011Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US79558529 févr. 20047 juin 2011Gamida Cell Ltd.Expansion of renewable stem cell populations
US797315613 juin 20085 juil. 2011Quark Pharmaceuticals Inc.Hypoxia-regulated genes
US799850912 nov. 200916 août 2011Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US800090030 déc. 200516 août 2011Microsoft CorporationAssociation-based predictions of pathogen characteristics
US80078477 août 200630 août 2011Eytan BidermanFeeding formula appliance
US80129292 juil. 20096 sept. 2011Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated diseases
US80175865 janv. 200913 sept. 2011Ramot At Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US801981816 janv. 200713 sept. 2011Zlango Ltd.Communications network system and methods for using same
US803491421 sept. 200611 oct. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US803924028 sept. 200518 oct. 2011Yissum Reseach Development Company Of The Hebrew University Of JerusalemRecombinant human T2 RNase and uses thereof
US80535542 janv. 20098 nov. 2011Ramot At Tel-Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US806266015 mars 200622 nov. 2011Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US80675736 juil. 200629 nov. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19 and methods of using same
US806757416 janv. 200829 nov. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19, and methods of using same
US80713236 avr. 20076 déc. 2011The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesHuman monoclonal antibodies that bind human insulin like growth factors and their use
US808041729 nov. 200620 déc. 2011Gamida-Cell Ltd.Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells
US80881602 juin 20093 janv. 2012Multi-Gene Vascular Systems Ltd. (“MGVS”)Drug-eluting intravascular prostheses and methods of use
US81295149 févr. 20096 mars 2012Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US816349427 nov. 200324 avr. 2012Technion Research & Development Foundation Ltd.Method for assessing metastatic properties of breast cancer
US816818030 sept. 20091 mai 2012Technion Research & Development Foundation Ltd.Methods and compositions for modulating angiogenesis
US816885720 déc. 20071 mai 2012Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US81781285 déc. 200215 mai 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Nanoparticles containing polymeric nucleic acid homologs
US81933117 févr. 20115 juin 2012Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US82027246 oct. 201019 juin 2012Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US823654327 sept. 20107 août 2012Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US82525887 avr. 200428 août 2012Yeda Research And Development Co. Ltd.Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
US828791223 juin 201116 oct. 2012Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US829320922 oct. 200923 oct. 2012Segev Laboratories LimitedSystem for delivering therapeutic agents into living cells and cells nuclei
US832363628 juil. 20114 déc. 2012Prolor Biotech Ltd.Long-acting interferons and derivatives thereof and methods thereof
US833786814 oct. 200925 déc. 2012Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US835203124 mai 20078 janv. 2013Impulse Dynamics NvProtein activity modification
US83673928 sept. 20095 févr. 2013Transalgae Ltd.Genetic transformation of algal and cyanobacteria cells by microporation
US837532716 janv. 200612 févr. 2013Zlango Ltd.Iconic communication
US83889548 avr. 20045 mars 2013Laboratoire Francais Du Fractionnement Et Des BiotechnologiesStabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
US841531820 juin 20119 avr. 2013Vascular Biogenics Ltd.Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US842616627 juil. 201123 avr. 2013Prolor Biotech Inc.Long-acting polypeptides and methods of producing same
US842668219 avr. 201223 avr. 2013Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US84502692 août 201128 mai 2013Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
US84613031 août 200811 juin 2013Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US846594828 juil. 201118 juin 2013Prolor Biotech Ltd.Long-acting veterinary polypeptides and methods of producing and administering same
US847853530 déc. 20052 juil. 2013Microsoft CorporationSystems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US84818123 juin 20099 juil. 2013Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants generated thereby
US848644130 nov. 201016 juil. 2013Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US851299020 août 201020 août 2013Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US85134889 avr. 200820 août 2013Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US85632739 avr. 200922 oct. 2013Tel Aviv University Future Technology Development L.P.Method of screening for compounds that disaggregate amyloid aggregates
US86178671 janv. 201231 déc. 2013Yissum Research Develpment Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US86423308 août 20064 févr. 2014Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US86581676 déc. 201225 févr. 2014Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US865838913 mars 200925 févr. 2014Ventana Medical Systems, Inc.Antibody conjugates
US86794851 août 200825 mars 2014Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US86800621 juin 200725 mars 2014Deliversir Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US86802464 févr. 201125 mars 2014Gilead Biologics, Inc.Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US868612214 janv. 20101 avr. 2014Ventana Medical Systems, Inc.Molecular conjugate
US868622724 juil. 20081 avr. 2014Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US869763422 déc. 200915 avr. 2014Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US87351279 sept. 201327 mai 2014Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US87478555 avr. 200910 juin 2014Technion Research & Development Foundation LimitedAnti human immunodeficiency antibodies and uses thereof
US875929214 févr. 201224 juin 2014Prolor Biotech, LlcLong-acting coagulation factors and methods of producing same
US877552616 janv. 20078 juil. 2014Zlango Ltd.Iconic communication
US88158239 mars 201226 août 2014Technion Research & Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US883486219 avr. 200516 sept. 2014Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US884639329 nov. 200630 sept. 2014Gamida-Cell Ltd.Methods of improving stem cell homing and engraftment
US884700821 mai 200930 sept. 2014Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant utility
US886515822 mai 201221 oct. 2014Ramot At Tel-Aviv University Ltd.Bacteriophages for reducing toxicity of bacteria
US892165828 oct. 200930 déc. 2014Evogene Ltd.Isolated polynucleotides encoding a MAP65 polypeptide and methods of using same for increasing plant yield
US892770025 févr. 20136 janv. 2015Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US89372201 mars 201020 janv. 2015Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield, biomass, vigor and/or growth rate of a plant
US894585225 mai 20113 févr. 2015Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V.Method for electrochemical detection of binding reactions
US894594326 mai 20113 févr. 2015The Board Of Trustees Of The University Of IllinoisPersonal glucose meters for detection and quantification of a broad range of analytes
US894615514 mars 20133 févr. 2015Opko Biologics Ltd.Long-acting polypeptides and methods of producing and administering same
US896291524 oct. 200624 févr. 2015Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
US899351026 août 201331 mars 2015Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US899967022 avr. 20137 avr. 2015Opko Biologics Ltd.Long-acting polypeptides and methods of producing same
US901272812 juil. 201021 avr. 2015Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US901844518 août 200928 avr. 2015Evogene Ltd.Use of CAD genes to increase nitrogen use efficiency and low nitrogen tolerance to a plant
US902334817 nov. 20095 mai 2015Technion Research & Development Foundation LimitedCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US90570929 nov. 201216 juin 2015Zetiq Technologies Ltd.Methods and compositions for identifying a cell phenotype
US909553319 nov. 20094 août 2015Technion Research & Development Foundation LimitedAntigen-presenting complex-binding compositions and uses thereof
US909664515 nov. 20114 août 2015Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
US90968658 juin 20104 août 2015Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
US91079355 janv. 201018 août 2015Gilead Biologics, Inc.Chemotherapeutic methods and compositions
US91210228 mars 20111 sept. 2015Monsanto Technology LlcMethod for controlling herbicide-resistant plants
US913258710 avr. 200815 sept. 2015Stratasys Ltd.System and method for three dimensional model printing
US915064411 avr. 20126 oct. 2015The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US915686522 oct. 201213 oct. 2015Deliversir LtdSystem for delivering therapeutic agents into living cells and cells nuclei
US917526619 juil. 20133 nov. 2015Gamida Cell Ltd.Enhancement of natural killer (NK) cell proliferation and activity
US91761396 mai 20133 nov. 2015Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US918240317 mai 201010 nov. 2015Zetiq Technologies Ltd.Kits for and methods of differential staining of cervical cancer cells and/or tissues
US92494071 juil. 20132 févr. 2016Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US928944714 sept. 201222 mars 2016Gilead Biologics, Inc.Chemotherapeutic methods and compositions
US929056424 mai 201222 mars 2016Mountgate Group LimitedCompositions and methods related to the prevention and treatment of rabies infection
US93032691 mai 20135 avr. 2016Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants
US931037314 févr. 201412 avr. 2016Ventana Medical Systems, Inc.Molecular conjugate
US93157892 janv. 201419 avr. 2016Ventana Medical Systems, Inc.Antibody conjugates
US932835327 avr. 20113 mai 2016Evogene Ltd.Isolated polynucleotides and polypeptides for increasing plant yield and/or agricultural characteristics
US941636313 sept. 201216 août 2016Monsanto Technology LlcMethods and compositions for weed control
US942255713 sept. 201223 août 2016Monsanto Technology LlcMethods and compositions for weed control
US942255813 sept. 201223 août 2016Monsanto Technology LlcMethods and compositions for weed control
US945843811 avr. 20114 oct. 2016Ben Gurion University Of The Negev Research And Development AuthoritySulfotransferase of a red microalga and uses thereof
US94584445 févr. 20134 oct. 2016Opko Biologics Ltd.Long-acting coagulation factors and methods of producing same
US946324128 janv. 201311 oct. 2016Laboratoire Francais Du Fractionnement Et Des BiotechnologiesMethod for stabilising an immunoglobulin G composition in liquid form
US94877938 juil. 20138 nov. 2016Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US94877962 févr. 20118 nov. 2016Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US949353417 avr. 201315 nov. 2016Opko Biologics Ltd.Long-acting oxyntomodulin variants and methods of producing same
US949378522 déc. 201015 nov. 2016Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
US95182675 nov. 201313 déc. 2016Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US952294517 avr. 201320 déc. 2016Opko Biologics Ltd.Long-acting oxyntomodulin variants and methods of producing same
US95406424 nov. 201410 janv. 2017The United States Of America, As Represented By The Secretary Of AgricultureCompositions and methods for controlling arthropod parasite and pest infestations
US955100621 déc. 201124 janv. 2017Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties
US955621020 avr. 201531 janv. 2017Sabag-Rfa Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US95622356 déc. 20107 févr. 2017A.B. Seeds Ltd.MicroRNA compositions and methods for enhancing plant resistance to abiotic stress
US956756829 sept. 201414 févr. 2017Enlivex Therapeutics Ltd.Method of preparing apoptotic monocytes
US956756919 juil. 201314 févr. 2017Gamida Cell Ltd.Methods of culturing and expanding mesenchymal stem cells
US957421029 juil. 201021 févr. 2017Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US961611212 janv. 201511 avr. 2017Technion Research & Development Foundation LimitedCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US963098922 juil. 201525 avr. 2017Ramot At Tel-Aviv University Ltd.Dipeptide analogs for treating conditions associated with amyloid fibril formation
US963100013 mars 201225 avr. 2017Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US96637789 mai 201430 mai 2017OPKO Biologies Ltd.Long-acting coagulation factors and methods of producing same
US967050122 avr. 20136 juin 2017Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US967684621 août 201513 juin 2017The United States Of America As Represented By The Secretary, Department Of Health And Human ServicesHuman monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US972658110 févr. 20148 août 2017Realbio Technologies Ltd.Sequential lateral flow capillary device for analyte determination
US977143110 oct. 201226 sept. 2017Ccam Biotherapeutics Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
US977728818 juil. 20143 oct. 2017Monsanto Technology LlcCompositions and methods for controlling leptinotarsa
US980853420 nov. 20137 nov. 2017Opko Biologics Ltd.Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20020142287 *14 déc. 20013 oct. 2002Hirotaka YamamotoHigh throughput assay to detect inhibitors of the map kinase pathway
US20030064058 *9 sept. 20023 avr. 2003Nadir AskenasyMethods of utilizing bone marrow stem cells for inducing immunological tolerance
US20030086914 *12 juil. 20028 mai 2003Yissum Research Development Company Of The Hebrew University Of JerusalemMethod and device for inducing biological processes by micro-organs
US20030104491 *30 oct. 20025 juin 2003Cabantchik Ioav ZviMolecules and methods using same for measuring non-transferrin bound iron
US20030114410 *27 nov. 200219 juin 2003Technion Research And Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030124116 *23 déc. 20023 juil. 2003Quark Biotech, Inc.Hypoxia-regulated genes
US20030152909 *17 déc. 200214 août 2003Mitrani Eduardo N.In vitro micro-organs, and uses related thereto
US20030211490 *10 janv. 200113 nov. 2003Hanan SteinPlants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US20040052769 *29 nov. 200118 mars 2004Yair ReisnerMethods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
US20040052928 *6 sept. 200218 mars 2004Ehud GazitPeptides and methods using same for diagnosing and treating amyloid-associated diseases
US20040078842 *17 janv. 200222 avr. 2004Aviah ZilbersteinChitinases, derived from carnivorous plants polynucleotide sequences encoding thereof, and methods of isolating and using same
US20040121442 *5 mai 200224 juin 2004Ilan ChetFungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
US20040146949 *27 oct. 200329 juil. 2004Jun TanMethods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US20040197334 *2 avr. 20037 oct. 2004Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20050008624 *9 févr. 200413 janv. 2005Tony PeledExpansion of renewable stem cell populations
US20050020499 *26 mai 200427 janv. 2005Bar Ilan UniversityMethods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US20050022269 *18 juil. 200227 janv. 2005Joseph HirschbergPolypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
US20050031618 *31 janv. 200210 févr. 2005Dror MevorachInduction of tolerance by apoptotic and/or necrotic cells
US20050054097 *29 janv. 200410 mars 2005Tony PeledEX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US20050054103 *4 mars 200410 mars 2005Tony PeledExpansion of renewable stem cell populations using modulators of PI 3-kinase
US20050085432 *16 déc. 200221 avr. 2005Aviva LapidotMethods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
US20050089939 *10 mai 200428 avr. 2005Jun TanAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US20050113327 *29 sept. 200426 mai 2005Levava RoizMethods of and compositions for inhibiting the proliferation of mammalian cells
US20050152912 *9 mars 200514 juil. 2005Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20050158822 *20 janv. 200421 juil. 2005Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20050176137 *11 avr. 200511 août 2005Technion Research & Development Foundation Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050176143 *11 avr. 200511 août 2005Technion Research & DevelopmentMethod and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US20050202098 *4 mai 200515 sept. 2005TolarenDisease therapy using dying or dead cells
US20050220774 *18 mars 20036 oct. 2005Tony PeledMethods of inducing differentiation in ex vivo expanded stem cells
US20050255101 *13 févr. 200217 nov. 2005Technion Research And Development Foundation Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20050271643 *12 août 20048 déc. 2005Iryna SorokulovaBacterial strains, compositions including same and probiotic use thereof
US20050287141 *15 août 200529 déc. 2005Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20060019340 *17 mai 200526 janv. 2006David NaorCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20060035980 *5 avr. 200516 févr. 2006Scanlan Thomas SThyronamine derivatives and analogs and methods of use thereof
US20060039897 *20 mars 200323 févr. 2006Tamar LotanStinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20060051426 *5 déc. 20029 mars 2006Gershon GolombNanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof
US20060079941 *11 oct. 200513 avr. 2006Eli OvsyshcherMethods and implantable devices for treating supraventricular arrhythmias
US20060083735 *25 mars 200420 avr. 2006Technion Research & Development Foundation Ltd.Antigen-presenting complex-binding compositions and uses thereof
US20060095241 *29 oct. 20044 mai 2006Microsoft CorporationSystems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060099273 *5 nov. 200411 mai 2006Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20060123516 *22 nov. 20058 juin 2006Gil RonenMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20060127366 *13 juil. 200315 juin 2006Mitrani Eduardo NMethod and device for inducing biological processes by micro-organs
US20060127402 *27 nov. 200315 juin 2006Technion Research & Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US20060134680 *21 déc. 200522 juin 2006Alexander KotlyarHomogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US20060148078 *30 nov. 20036 juil. 2006Sharon Gerecht-NirMethod of dynamically culturing embryonic stem cells
US20060159769 *15 mars 200620 juil. 2006Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20060190226 *30 déc. 200524 août 2006Microsoft CorporationSystems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060211064 *17 mars 200621 sept. 2006Hyesook KimDetection of hypertension using glucuronidated metabolic products
US20060234203 *19 avr. 200519 oct. 2006Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US20060234947 *21 juin 200619 oct. 2006Tel Aviv University Future Technology Development L.PPeptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20060246523 *27 avr. 20062 nov. 2006Christopher BieniarzAntibody conjugates
US20060246524 *28 avr. 20062 nov. 2006Christina BauerNanoparticle conjugates
US20060257429 *11 oct. 200416 nov. 2006Dreier Kimberly JVaccine for periodontal disease
US20060257865 *23 oct. 200216 nov. 2006Simon MallalMethod for identification and development of therapeutic agents
US20060260002 *20 juin 200416 nov. 2006Gil RonenNucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20070032421 *12 juin 20068 févr. 2007Efrat LevyMethods and compositions relating to cystatin C
US20070087437 *21 févr. 200619 avr. 2007Jifan HuMethods for rejuvenating cells in vitro and in vivo
US20070117153 *21 nov. 200624 mai 2007Christopher BieniarzMolecular conjugate
US20070134739 *12 déc. 200514 juin 2007Gyros Patent AbMicrofluidic assays and microfluidic devices
US20070135334 *23 janv. 200714 juin 2007Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20070160546 *10 janv. 200612 juil. 2007Tamar LotanUse of stinging cells/capsules for the delivery of active agents to keratinous substances
US20070184530 *5 févr. 20079 août 2007Fuad FaresLong-acting veterinary polypeptides and methods of producing and administering same
US20070190610 *1 févr. 200716 août 2007Fuad FaresLong-acting EPO polypeptides and derivatives thereof and methods thereof
US20070190611 *1 févr. 200716 août 2007Fuad FaresLong-acting polypeptides and methods of producing same
US20070196369 *18 oct. 200623 août 2007Hoogenboom Henricus Renerus JMHC-peptide complex binding ligands
US20070225242 *25 janv. 200727 sept. 2007The Board Of Trustees Of The Leland Stanford Junior UniversityMethod and composition for treating and preventing tumor metastasis in vivo
US20070264274 *21 mai 200715 nov. 2007Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US20070281037 *5 nov. 20046 déc. 2007Nanocyte Inc.Sterile preparations and compositions including stinging capsules and methods of producing and using same
US20070281883 *5 juin 20066 déc. 2007Hanna RosenfeldDevelopment of follicle stimulating hormone agonists and antagonists in fish
US20070292930 *17 avr. 200720 déc. 2007Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of producing recombinant Aspergillus niger beta-glucosidase and an aroma spreading plant
US20080004234 *1 juin 20073 janv. 2008Segev Laboratories LimitedSystem for delivering therapeutic agents into living cells and cells nuclei
US20080082678 *16 janv. 20063 avr. 2008Zlango Ltd.Communications Network System and Methods for Using Same
US20080131419 *28 sept. 20055 juin 2008Yissum Research Development Company Of The Hebrew University Of JerusalemRecombinant Human T2 Rnase and Uses Thereof
US20080199895 *4 oct. 200721 août 2008Yeda Research And Development Co. Ltd.Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
US20080312179 *25 juil. 200818 déc. 2008Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5'-UTR
US20090013087 *16 janv. 20078 janv. 2009Zlango Ltd.Communications Network System and Methods For Using Same
US20090053224 *1 août 200826 févr. 2009Arresto BiosciencesLox and loxl2 inhibitors and uses thereof
US20090068207 *11 avr. 200612 mars 2009Vascular Biogenics Ltd.Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US20090089898 *15 août 20062 avr. 2009Hagai KarchiMethods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US20090104201 *1 août 200823 avr. 2009Victoria SmithMethods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US20090121709 *5 janv. 200914 mai 2009Ramot At Tel Aviv University Ltd.Peptide nanostructures encapsulating A foreign material and method of manufacturing same
US20090123553 *2 janv. 200914 mai 2009Ramot At Tel Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US20090126042 *14 juin 200514 mai 2009Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20090143321 *6 juil. 20064 juin 2009Avraham HochbergNucleic acid agents for downregulating h19 and methods of using same
US20090156471 *14 juil. 200518 juin 2009Ramot At Tel Aviv University Ltd.Use of anti-amyloid agents for treating and typing pathogen infections
US20090176253 *13 mars 20099 juil. 2009Christopher BieniarzAntibody conjugates
US20090181398 *16 mars 200916 juil. 2009Christina BauerNanoparticle conjugates
US20090209041 *9 avr. 200920 août 2009Tel Aviv University Future Technology Development L.P.Peptides and methods for inhibiting amyloid formation
US20090221681 *21 sept. 20063 sept. 2009Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20090253170 *9 févr. 20098 oct. 2009Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US20090260109 *3 juin 200915 oct. 2009Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants genterated thereby
US20090293146 *20 déc. 200726 nov. 2009Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US20100022459 *2 juil. 200928 janv. 2010Tel Aviv University Future Technology Development L.PPeptides directed for diagnosis and treatment of amyloid-associated diseases
US20100055033 *6 avr. 20074 mars 2010The Government Of The United States Of America As Represented By The SecretaryAntibody compositions and methods for treatment of neoplastic disease
US20100055058 *12 nov. 20094 mars 2010Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US20100068135 *8 août 200618 mars 2010Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20100080805 *17 nov. 20091 avr. 2010Technion Research & DevelopmentCompositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20100081177 *8 sept. 20091 avr. 2010TransAlgae LtdDecreasing RUBISCO content of algae and cyanobacteria cultivated in high carbon dioxide
US20100088037 *26 août 20098 avr. 2010Epipop Pty Ltd.Method for Identification and Development of Therapeutic Agents
US20100092386 *22 oct. 200915 avr. 2010David SegevSystem for delivering therapeutic agents into living cells and cells nuclei
US20100105608 *22 déc. 200929 avr. 2010Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US20100105759 *16 janv. 200829 avr. 2010Abraham HochbergH19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100111869 *14 oct. 20096 mai 2010Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20100119515 *30 sept. 200913 mai 2010Gera NeufeldPharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US20100136652 *14 janv. 20103 juin 2010Christopher BieniarzMolecular Conjugate
US20100196403 *27 janv. 20085 août 2010Jacob HochmanAntibody conjugates for circumventing multi-drug resistance
US20100221233 *8 mars 20102 sept. 2010University Of South FloridaCompositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20100228007 *16 mars 20109 sept. 2010Technion Research & Development Foundation Ltd.Mhc-peptide complex binding ligands
US20110008314 *27 sept. 201013 janv. 2011Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US20110020357 *5 avr. 200927 janv. 2011Technion Research & Development Foundation Ltd.Anti human immunodeficiency antibodies and uses thereof
US20110027887 *18 oct. 20103 févr. 2011Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US20110033473 *5 avr. 200910 févr. 2011Yoram ReiterAnti influenza antibodies and uses thereof
US20110040248 *17 août 201017 févr. 2011Closed Loop Therapies BvMethods and implantable devices for treating supraventricular arrhythmias
US20110052501 *1 févr. 20093 mars 2011Liat DassaPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US20110070224 *30 nov. 201024 mars 2011Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20110081706 *28 sept. 20107 avr. 2011TransAlgae LtdMethod and system for efficient harvesting of microalgae and cyanobacteria
US20110091454 *8 févr. 201021 avr. 2011Alex DiberMethods and systems for annotating biomolecular sequences
US20110116972 *14 oct. 201019 mai 2011Mats HolmquistMicrofluidic assays and microfluidic devices
US20110147993 *10 avr. 200823 juin 2011Objet Geometries Ltd.System and method for three dimensional model printing
US20110150874 *20 déc. 201023 juin 2011Teva Pharmaceutical Industries Ltd.Fusion proteins, uses thereof and processes for producing same
US20110197315 *28 oct. 200911 août 2011Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield
US20110207144 *20 août 201025 août 2011Derek MarshallIn vitro screening assays
USRE31006 *2 mars 19783 août 1982Akzona IncorporatedProcess for the demonstration and determination of reaction components having specific binding affinity for each other
USRE32696 *22 déc. 197814 juin 1988Akzona IncorporatedEnzymatic immunological method for determination of antigens and antibodies
DE102015220401A120 oct. 201519 mai 2016Gen-Probe IncorporatedErythrozyten-Lyselösung
EP0022768A1 *5 nov. 197928 janv. 1981Syva CoMacromolecular environment control in specific receptor assays.
EP0022768A4 *5 nov. 197918 août 1980Syva CoMacromolecular environment control in specific receptor assays.
EP0023989A1 *18 juil. 198018 févr. 1981Medac Gesellschaft für klinische Spezialpräparate mbHEnzyme-immuno assay for the detection of pathogen specific antibodies and test-kit for performing this assay
EP0032286A2 *26 sept. 198022 juil. 1981Syva CompanyMethod for analysis for a member of an immunological pair using a test surface; kit and test surface material therefor
EP0032286A3 *26 sept. 19805 août 1981Syva CompanyMethod for analysis for a member of an immunological pair using a test surface; kit and test surface material therefor
EP0040365A1 *7 mai 198125 nov. 1981Pharmacia Diagnostics AbAn assaying method involving biospecific affinity reactions
EP0040728A1 *7 mai 19812 déc. 1981Pharmacia Diagnostics AbAn improvement in and relating to assaying methods involving biospecific affinity reactions
EP0054675A1 *22 oct. 198130 juin 1982Boehringer Mannheim GmbhProcess for enzyme immuno-determination in the heterogeneous phase
EP0124352A2 *26 avr. 19847 nov. 1984TECHNICON INSTRUMENTS CORPORATION(a Delaware corporation)Protected binding assay
EP0124352A3 *26 avr. 198417 sept. 1986Technicon Instruments CorporationProtected binding assay
EP0524502A29 juil. 199227 janv. 1993Bayer CorporationImmunoassay for free analyte
EP1683874A229 août 200126 juil. 2006YEDA RESEARCH AND DEVELOPMENT Co. LTD.Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
EP2058275A17 janv. 200413 mai 2009Ramot at Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP2062918A227 nov. 200327 mai 2009Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2062919A227 nov. 200327 mai 2009Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2071021A212 déc. 200817 juin 2009University of South FloridaBone marrow-derived neuronal cells
EP2072045A211 févr. 200324 juin 2009Technion Research and Development Foundation, Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP2116618A18 mai 200911 nov. 2009Agency for Science, Technology And ResearchDiagnosis and treatment of Kawasaki disease
EP2174668A214 nov. 200514 avr. 2010Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
EP2182052A17 oct. 20035 mai 2010Technion Research and Development Foundation, Ltd.Human foreskin cells suitable for culturing stem cells
EP2186530A115 nov. 200119 mai 2010Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same
EP2208782A24 févr. 200021 juil. 2010Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2216033A24 mars 200411 août 2010Yeda Research and Development Co. Ltd.Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
EP2237037A112 déc. 20056 oct. 2010Gyros Patent AbMicrofluidic device and use thereof
EP2279726A225 mai 20062 févr. 2011Biorest Ltd.Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
EP2289567A215 déc. 20042 mars 2011Regentis Biomaterials Ltd.Matrix comprising naturally-occurring crosslinked protein backbone
EP2295980A130 oct. 200316 mars 2011Yissum Research Development Company, of The Hebrew University of JerusalemMolecules and methods using same for measuring non-transferrin bound iron
EP2305794A126 janv. 20036 avr. 2011Gamida Cell Ltd.Expansion of renewable stem cell populations
EP2308994A121 mars 200213 avr. 2011Yeda Research And Development Co., Ltd.Methods for determining a risk to develop cancer
EP2311938A14 févr. 200020 avr. 2011Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2316441A116 févr. 20064 mai 2011Hadasit Medical Research Services And DevelopmentBisphosphonates for treating endometriosis
EP2316950A119 mars 20014 mai 2011Technion Research and Development Foundation, Ltd.Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP2319857A24 mars 200411 mai 2011Yeda Research And Development Co., Ltd.Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
EP2322561A15 oct. 200418 mai 2011Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2329814A111 févr. 20038 juin 2011Technion Research and Development Foundation, Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer
EP2330132A14 avr. 20048 juin 2011Yeda Research and Development Co. Ltd.Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
EP2336330A214 juin 200522 juin 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2338896A211 déc. 200329 juin 2011R.B.T. (Rakuto Bio Technologies) Ltd.Use of lignin peroxidase in skin and hair lightening
EP2343373A114 juin 200513 juil. 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2354164A15 oct. 200410 août 2011Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2357478A230 nov. 200117 août 2011Crawford Healthcare Holdings LimitedDiagnosis of disease
EP2359853A17 août 200124 août 2011Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2359854A17 août 200124 août 2011Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2365087A220 mai 200414 sept. 2011Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2366775A122 mars 200721 sept. 2011Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2383345A120 déc. 20072 nov. 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2390312A129 nov. 200630 nov. 2011Gamida Cell Ltd.Methods of improving stem cell homing and engraftment
EP2390664A125 mai 201030 nov. 2011Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Method for electrochemical detection of binding reactions
EP2425841A122 nov. 20017 mars 2012Vascular Biogenics Ltd.Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
EP2441840A118 juil. 200618 avr. 2012Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2457999A27 déc. 200330 mai 2012Technion Research & Development Foundation Ltd.Culture medium for pluropotent stem cells
EP2463382A17 déc. 201113 juin 2012Enterologics, Inc.Method for identifying E. Coli M-17
EP2465920A225 févr. 201020 juin 2012Tel HaShomer Medical Research Infrastructure and Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
EP2465924A218 juin 200620 juin 2012Ramot at Tel-Aviv University Ltd.Isolated cells and populations comprising same for the treament of cns diseases
EP2471807A15 févr. 20074 juil. 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2478924A131 janv. 200825 juil. 2012Technion Research & Development FoundationAlbumin fibers and fabrics and methods of generating and using same
EP2484768A218 juil. 20068 août 2012Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2487182A29 juil. 200615 août 2012FULCRUM SP Ltd.SP1 polypeptides, modified SP1 polypeptides and uses thereof
EP2500428A210 juil. 200819 sept. 2012Yeda Research and Development Co. Ltd.Nucleic acid construct systems capable of diagnosing or treating a cell state
EP2514315A221 août 200624 oct. 2012Yeda Research and Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
EP2514766A227 mars 200824 oct. 2012Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
EP2526952A115 juil. 200428 nov. 2012Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526953A115 juil. 200428 nov. 2012Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2527441A215 juil. 200828 nov. 2012Technion Research & Development FoundationCompositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
EP2529754A13 mai 20085 déc. 2012Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
EP2532674A15 févr. 200712 déc. 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2532675A15 févr. 200712 déc. 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2540301A215 juil. 20042 janv. 2013Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2540302A115 juil. 20042 janv. 2013Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2548951A122 mars 200723 janv. 2013Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2550982A126 juil. 201230 janv. 2013Technion Research & Development Foundation Ltd.Devices for surgical applications
EP2561889A231 juil. 200327 févr. 2013Yeda Research and Development Co. Ltd.Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
EP2581445A17 août 200817 avr. 2013Yeda Research And Development Co. Ltd.Regulators of MMP-9 and uses thereof
EP2591789A22 sept. 200815 mai 2013Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP2599790A126 nov. 20085 juin 2013Yissum Research Development Company of The Hebrew University of JerusalemCompositions comprising fibrous polypeptides and polysachharides
EP2620493A126 mai 200931 juil. 2013Ramot at Tel Aviv University Ltd.Mesenchymal stem cells for the treatment of CNS diseases
EP2626417A122 mars 200714 août 2013Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2633854A13 déc. 20094 sept. 2013Yeda Research And Development Co. Ltd.miRNA-9 or miRNA-9* for use in treating MND
EP2641606A126 mai 200925 sept. 2013Pluristem Ltd.Methods of treating inflammatory colon diseases
EP2657342A110 août 200930 oct. 2013Genisphere Inc.DNA dendrimers protected against nuclease degradation are useful as vectors for the delivery of siRNA
EP2716654A124 oct. 20069 avr. 2014Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
EP2719394A129 juin 200416 avr. 2014Tel Aviv University Future Technology Development L.P.Peptides antibodies directed thereagainst for diagnosing and treating amyloid-associated diseases
EP2781223A12 oct. 200824 sept. 2014Rappaport Family Institute for Research in the Medical SciencesCompositions comprising semaphorins for the treatment of angiogenesis related diseases
EP2789626A223 sept. 200915 oct. 2014Tel Hashomer Medical Research Infrastructure and Services Ltd.Peptides and compositions for prevention of cell adhesion and methods of using same
EP2806023A229 nov. 201026 nov. 2014Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2808402A229 déc. 20093 déc. 2014Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment
EP2816117A228 sept. 200524 déc. 2014Collplant Ltd.Collagen producing plants and methods of generating and using same
EP2839839A128 févr. 200825 févr. 2015Yeda Research And Development Company LimitedNuclear targeting sequences
EP2853536A15 févr. 20071 avr. 2015OPKO Biologics Ltd.Long-acting erythropoietin polypeptides and uses thereof
EP2853541A15 févr. 20071 avr. 2015OPKO Biologics Ltd.Long-acting polypeptides and uses thereof
EP2862929A19 déc. 201022 avr. 2015Quark Pharmaceuticals, Inc.Compositions and methods for treating diseases, disorders or injury of the CNS
EP2889041A126 juil. 20061 juil. 2015Rutgers, The State University of New JerseyKit of reagents for tuberculosis assay
EP2910638A224 juil. 200826 août 2015Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
EP2923709A128 mars 201430 sept. 2015Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccine
EP2936976A121 avr. 200928 oct. 2015Danziger Innovations Ltd.Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
EP2977445A229 nov. 201027 janv. 2016Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
EP2990421A129 avr. 20102 mars 2016Tel HaShomer Medical Research Infrastructure and Services Ltd.Anti ceacam1 antibodies and methods of using same
EP2992895A18 sept. 20149 mars 2016Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Three-component-multistage malaria vaccine
EP2995194A115 août 200616 mars 2016Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP3000889A21 mars 201030 mars 2016Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
EP3006039A12 mars 200513 avr. 2016Acceleron Pharma Inc.Alk7 polypeptides for use in promoting fat loss
EP3020410A116 avr. 200918 mai 2016Collplant Ltd.Methods of generating and using procollagen
EP3026057A29 mars 20101 juin 2016Ramot at Tel Aviv University Ltd.Compositions for prevention and treatment of neurodegenerative diseases
EP3032259A11 mai 200815 juin 2016Tel Hashomer Medical Research Infrastructure and Services Ltd.Methods for detecting trophoblast cells in maternal blood based on cytokeratin-7
EP3034087A16 déc. 201222 juin 2016Yeda Research and Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
EP3056569A222 déc. 201017 août 2016Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
EP3072972A218 août 200928 sept. 2016Evogene Ltd.Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
EP3075396A110 oct. 20115 oct. 2016Yeda Research and Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
EP3075854A115 juil. 20085 oct. 2016Technion Research & Development Foundation Ltd.Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
EP3088528A128 sept. 20052 nov. 2016Collplant Ltd.Collagen producing plants and methods of generating and using same
EP3091071A122 mars 20079 nov. 2016Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP3103463A12 sept. 200814 déc. 2016Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP3115451A11 sept. 200911 janv. 2017Pluristem Ltd.Adherent cells from placenta tissue and use thereof in therapy
EP3130346A11 juil. 201015 févr. 2017OPKO Biologics Ltd.Long-acting factor vii coagulation factors
EP3159405A15 janv. 201126 avr. 2017Vascular Biogenics Ltd.Methods for use of a specific anti-angiogenic adenoviral agent
EP3176183A11 déc. 20167 juin 2017Yeda Research and Development Co. LtdCompositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
EP3184109A129 déc. 201028 juin 2017Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
EP3202779A25 févr. 20079 août 2017OPKO Biologics Ltd.Long-acting hgh polypeptides and uses thereof
EP3208338A12 août 201223 août 2017Yeda Research and Development Co., Ltd.Micro-rna mir-15 and compositions comprising same for the treatment of corticotropin-releasing hormone- associated medical conditions
EP3216805A127 janv. 201113 sept. 2017Yeda Research and Development Co. LtdAntibodies that inhibit metalloproteins
WO1980002747A1 *19 mai 198011 déc. 1980Rapidex LtdUltrasensitive enzymatic radioimmunoassay method
WO1982004323A1 *28 mai 19829 déc. 1982O Neill SeanImmunoprecipitation assay
WO2002044736A230 nov. 20016 juin 2002Molecular Skincare LimitedDiagnosis and treatment of epidermal or skin diseases
WO2004060135A231 déc. 200322 juil. 2004Rappaport Family Institute For Research In The Medical SciencesMethods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2005033142A25 oct. 200414 avr. 2005Yeda Research And Development Co. Ltd.Anti-nik antibodies and uses thereof
WO2005033145A15 oct. 200414 avr. 2005Yeda Research And Development Co. Ltd.Antibodies to nik, their preparation and use
WO2005051423A230 nov. 20049 juin 2005Yeda Research And Development Co. LtdMethods and agents for immune modulation and methods for identifying immune modulators
WO2006090388A223 févr. 200631 août 2006The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterFruit cell culture extract for treating inflammation
WO2006134602A218 juin 200621 déc. 2006Ramot At Tel Aviv University Ltd.Isolated cells and populations comprising same for the treatment of cns diseases
WO2007020638A215 août 200622 févr. 2007Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
WO2007023491A221 août 20061 mars 2007Yeda Research And Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007031996A111 sept. 200622 mars 2007Rappaport Family Institute For Research In The Medical SciencesCompositions and methods for diagnosing and treating an inflammation
WO2007034487A121 sept. 200629 mars 2007Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
WO2007091254A16 févr. 200716 août 2007Rappaport Family Institute For Research In The Medical SciencesMethods and kit for diagnosing t1dm
WO2007094985A25 févr. 200723 août 2007Modigene IncLong-acting polypeptides and methods of producing and administering same
WO2007110869A228 mars 20074 oct. 2007Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to warfarin resistance
WO2008010228A222 juil. 200724 janv. 2008Yeda Research And Development Co. Ltd.Photosyntheticorganisms and compositions and methods of generating same
WO2008026198A215 août 20076 mars 2008Yeda Research And Development Co. Ltd.Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
WO2008041183A22 oct. 200710 avr. 2008Technion Research & Development Foundation Ltd.Microtubes and methods of producing same
WO2008093341A231 janv. 20087 août 2008Technion Research & Development Foundation Ltd.Electrospun scaffolds and methods of generating and using same
WO2008093342A231 janv. 20087 août 2008Technion Research & Development Foundation Ltd.Albumin fibers and fabrics and methods of generating and using same
WO2008120202A227 mars 20089 oct. 2008Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120216A12 avr. 20089 oct. 2008Ramot At Tel Aviv University Ltd.Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
WO2008132753A21 mai 20086 nov. 2008Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for detecting fetal cells in the maternal blood
WO2009010968A215 juil. 200822 janv. 2009Yitzchak HillmanDisease treatment via antimicrobial peptides or their inhibitors
WO2009034574A211 sept. 200819 mars 2009Yeda Research And Development Co. Ltd.Methods of treating tumors in immune-privileged sites
WO2009083958A223 déc. 20089 juil. 2009Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009104174A212 févr. 200927 août 2009Technion Research & Development Foundation Ltd .A method of attaching a cell-of-interest to a microtube
WO2010016806A17 août 200911 févr. 2010Agency For Science, Technology And Research (A*Star)Vhz for diagnosis and treatment of cancers
WO2010017544A210 août 200911 févr. 2010Genisphere, Inc.Long-acting dna dendrimers and methods thereof
WO2010029545A210 sept. 200918 mars 2010Ben Gurion University Of The Negev Research And Development AuthorityCompositions and methods for treating s. pneumoniae infection
WO2010031006A114 sept. 200918 mars 2010Cryopraxis Criobiologia Ltda.Ischemic tissue cell therapy
WO2010035261A224 sept. 20091 avr. 2010Ben Gurion University Of The Negev Research And Development AuthorityAmyloid beta-peptides and methods of use thereof
WO2010049897A228 oct. 20096 mai 2010Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
WO2010055525A117 nov. 200920 mai 2010Technion Research & Development Foundation Ltd.Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A117 nov. 200927 mai 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A124 nov. 20093 juin 2010Biodalia Microbiological Technologies Ltd.A method of in-situ enrichment of foods with fructan
WO2010064231A129 nov. 200910 juin 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A13 déc. 200910 juin 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to cancer
WO2010071610A121 déc. 200924 juin 2010Agency For Science, Technology And Research (A*Star)Severe chikungunya biomarkers
WO2010076642A128 déc. 20098 juil. 2010Tel Hashomer Medical Research, Infrastructure And Services LtdPeptides and compositions for prevention of cell adhesion and methods of using same
WO2010076756A228 déc. 20098 juil. 2010Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
WO2010076788A229 déc. 20098 juil. 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010076794A130 déc. 20098 juil. 2010Technion Research & Development Foundation Ltd.Method of denitrifying brine and systems capable of same
WO2010086856A231 janv. 20105 août 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2010086867A22 févr. 20105 août 2010Ramot At Tel Aviv University Ltd.Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A14 févr. 201012 août 2010Yeda Research And Development Co. Ltd.Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2010097793A225 févr. 20102 sept. 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
WO2010097794A125 févr. 20102 sept. 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of reprogramming renal cells
WO2010100595A21 mars 201010 sept. 2010Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2010103517A110 mars 201016 sept. 2010Rappaport Family Institute For Research In The Medical SciencesSoluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A128 mars 20107 oct. 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of predicting clinical course and treating multiple sclerosis
WO2010113146A128 févr. 20107 oct. 2010The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical CenterA method of regulating proliferation and differentiation of keratinocyes
WO2010116375A18 avr. 201014 oct. 2010Yeda Research And Development Co. Ltd.Isolated peptides for regulating apoptosis
WO2010137013A125 mai 20102 déc. 2010Ramot At Tel Aviv University Ltd.Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137017A226 mai 20102 déc. 2010Yeda Research And Development Co. Ltd.Proteasome inhibitors and uses thereof
WO2010137020A127 mai 20102 déc. 2010Yeda Research And Development Co. Ltd.Methods of treating inflammation
WO2010137021A227 mai 20102 déc. 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of generating connective tissue
WO2010150259A124 juin 201029 déc. 2010Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical CenterMethods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2011004361A21 juil. 201013 janv. 2011Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
WO2011004379A18 juil. 201013 janv. 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.Compositions and methods for treating cancer
WO2011010309A121 juil. 201027 janv. 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.A method of diagnosing cancer
WO2011013130A229 juil. 20103 févr. 2011Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011021171A122 août 201024 févr. 2011Beeologics, LlcPreventing and curing beneficial insect diseases via plant transcribed molecules
WO2011021194A217 août 201024 févr. 2011Technion Research & Development Foundation Ltd.Pericyte progenitor cells and methods of generating and using same
WO2011024172A226 août 20103 mars 2011Technion Research & Development Foundation Ltd.Liposomal compositions and uses of same
WO2011030329A131 août 201017 mars 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating tumors
WO2011030332A25 sept. 201017 mars 2011Yeda Research And Development Co. Ltd.Methods for hematopoietic precursor mobilization
WO2011030336A16 sept. 201017 mars 2011Ramot At Tel-Aviv University Ltd.Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011033506A215 sept. 201024 mars 2011Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2011033511A116 sept. 201024 mars 2011Ramot At Tel-Aviv University Ltd.Peptides for the treatment of oxidative stress related disorders
WO2011045796A114 oct. 201021 avr. 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2011046570A116 oct. 200921 avr. 2011The University Of Medicine And Dentistry Of New JerseyMethod for treating chronic nerve tissue injury using a cell therapy strategy
WO2011048600A121 oct. 201028 avr. 2011Danziger Innovations Ltd.Generating genotypic variations in plant genomes by gamete infection
WO2011055366A18 nov. 201012 mai 2011Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of IsraelMo-1 conditional knock-out non-human animal and uses thereof
WO2011058555A111 nov. 201019 mai 2011Yeda Research And Development Co. Ltd.A method of editing dna in a cell and constructs capable of same
WO2011058557A111 nov. 201019 mai 2011Ramot At Tel-Aviv University Ltd.Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011061736A117 nov. 201026 mai 2011Protalix Ltd.Alkaline alpha galactosidase for the treatment of fabry disease
WO2011064669A229 nov. 20103 juin 2011Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
WO2011064773A124 nov. 20103 juin 2011Collplant Ltd.Method of generating collagen fibers
WO2011067745A26 déc. 20109 juin 2011Rosetta Green Ltd.Compositions and methods for enhancing plants resistance to abiotic stress
WO2011072091A19 déc. 201016 juin 2011Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the cns
WO2011080674A222 déc. 20107 juil. 2011Evogene Ltd.Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2011080740A129 déc. 20107 juil. 2011Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
WO2011086509A112 janv. 201121 juil. 2011Vascular Biogenics Ltd.Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011092700A127 janv. 20114 août 2011Yeda Research And Development Co. Ltd.Antibodies that inhibit metalloproteins
WO2011099006A210 févr. 201118 août 2011Yeda Research And Development Co. Ltd.Enzymatic systems for carbon fixation and methods of generating same
WO2011104708A223 févr. 20111 sept. 2011Ben Gurion University Of The Negev Research And Development AuthorityMethods for inhibiting necrosis
WO2011107939A11 mars 20119 sept. 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A13 mars 20119 sept. 2011Yeda Research And Development Co. Ltd.Methods of measuring protein stability
WO2011111034A125 janv. 201115 sept. 2011Yeda Research And Development Co. Ltd.Recombinant protein production in heterologous systems
WO2011111050A210 mars 201115 sept. 2011Jacob EdreiMethods of generating hydrogen
WO2011125015A24 avr. 201113 oct. 2011Bar-Ilan UniversityProtease-activatable pore-forming polypeptides
WO2011128897A112 avr. 201120 oct. 2011Technion Research & Development Foundation Ltd.Populations of pancreatic progenitor cells and methods of isolating and using same
WO2011132182A122 mars 201127 oct. 2011Yeda Research And Development Co. Ltd.MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2011135527A227 avr. 20113 nov. 2011Evogene Ltd.Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
WO2011138776A24 mai 201110 nov. 2011Hervana Ltd.Biologic female contraceptives
WO2011138778A24 mai 201110 nov. 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of identifying inhibitors of polypeptides-of-interest
WO2011138785A25 mai 201110 nov. 2011Rappaport Family Institute For Research In The Medical SciencesUse of ccl1 in therapy
WO2011141914A112 mai 201117 nov. 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of adult renal cells and methods of isolating and using same
WO2011147563A125 mai 20111 déc. 2011Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Method for electrochemically detecting binding reactions
WO2011150186A1 *26 mai 20111 déc. 2011The Board Of Trustees Of The University Of IllinoisPersonal glucose meters for detection and quantification of a broad range of analytes
WO2011151833A12 juin 20118 déc. 2011Ramot At Tel-Aviv University Ltd.Methods of treating diabetes and compositions capable of same
WO2011154940A16 juin 201115 déc. 2011Osnat Ashur-FabianMethods and kits for diagnosing conditions related to hypoxia
WO2011158242A216 juin 201122 déc. 2011Futuragene Israel Ltd.Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2011158243A216 juin 201122 déc. 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of diagnosing and treating cancer
WO2012007919A214 juil. 201119 janv. 2012Technion Research & Development Foundation Ltd.Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007950A214 juil. 201119 janv. 2012Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007951A114 juil. 201119 janv. 2012Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012011113A221 juil. 201126 janv. 2012Shai YarkoniRegulatory immune cells with enhanced targeted cell death effect
WO2012014205A127 juil. 20112 févr. 2012Technion Research & Development Foundation Ltd.Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014207A227 juil. 20112 févr. 2012Technion Research & Development Foundation Ltd.Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014208A227 juil. 20112 févr. 2012Yeda Research And Development Co. Ltd.Methods and systems for assessing clonality of cell cultures
WO2012017439A24 août 20119 févr. 2012Ramot At Tel-Aviv University Ltd.Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012025914A17 juil. 20111 mars 2012Ramot At Tel-Aviv University Ltd.Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A124 août 20111 mars 2012Rappaport Family Institute For Research In The Medical SciencesMethods of improving transplantation using sdf-1alpha
WO2012032510A16 sept. 201115 mars 2012Yeda Research And Development Co. Ltd.Primers for amplifying dna and methods of selecting same
WO2012032519A27 sept. 201115 mars 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of diagnosing parkinson's disease
WO2012032520A17 sept. 201115 mars 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032521A27 sept. 201115 mars 2012Technion Research & Development Foundation Ltd.Novel methods and culture media for culturing pluripotent stem cells
WO2012032525A28 sept. 201115 mars 2012Yeda Research And Development Co. Ltd.An immunosuppressive drug combination for a stable and long term engraftment
WO2012032526A28 sept. 201115 mars 2012Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012035539A115 sept. 201122 mars 2012Ramot At Tel-Aviv University Ltd.Methods of expanding and redifferentiating islet beta cells
WO2012038956A120 sept. 201129 mars 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating neurodegenerative diseases
WO2012052872A210 oct. 201126 avr. 2012Yeda Research And Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A112 oct. 201126 avr. 2012Vascular Biogenics Ltd.Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012056452A227 oct. 20113 mai 2012Nanocyte (Israel) Ltd.Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A127 oct. 20113 mai 2012Yeda Research And Development Co. Ltd.Methods of generating antibodies to metalloenzymes
WO2012059922A23 nov. 201110 mai 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Transgenic plants with improved saccharification yields and methods of generating same
WO2012059925A23 nov. 201110 mai 2012Ben-Gurion University Of The Negev Research And Development AuthorityAcyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
WO2012066495A217 nov. 201124 mai 2012Ben Gurion University Of The Negev Research And Development AuthorityT-cell therapy to neurodegenerative diseases
WO2012081029A115 déc. 201121 juin 2012Kadimastem Ltd.Insulin producing cells derived from pluripotent stem cells
WO2012090205A228 déc. 20115 juil. 2012Kamedis Ltd.Plant extracts for the treatment and prevention of infections
WO2012098537A17 sept. 201126 juil. 2012Protalix Ltd.Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012104851A131 janv. 20129 août 2012Yeda Research And Development Co. Ltd.Methods of diagnosing disease using overlap extension pcr
WO2012114339A123 févr. 201230 août 2012Rappaport Family Institute For Research In The Medical SciencesHigh affinity molecules capable of binding a type a plexin receptor and uses of same
WO2012117373A11 mars 20127 sept. 2012Ramot At Tel-Aviv University Ltd.Genetically modified muscle cells which express neurotrophic factors
WO2012117406A21 mars 20127 sept. 2012Futuragene Israel Ltd.Bacterial resistant transgenic plants
WO2012120500A25 mars 201213 sept. 2012Merck Serono S.A.Low fucose cell lines and uses thereof
WO2012120518A18 mars 201213 sept. 2012Ramot At Tel-Aviv University Ltd.Compositions and methods for diagnosing and treating phenylketonuria (pku)
WO2012123938A126 févr. 201220 sept. 2012Tel Hashomer Medical Research Infrastructure And Services Ltd.Quinolone analogs for treating autoimmune diseases
WO2012123949A115 mars 201220 sept. 2012Ramot At Tel-Aviv University Ltd.Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012127320A122 mars 201227 sept. 2012Pluristem Ltd.Methods for treating radiation or chemical injury
WO2012127475A122 mars 201227 sept. 2012Neurim Pharmaceuticals (1991) Ltd.Neuroprotective peptides
WO2012131680A228 mars 20124 oct. 2012Yeda Research And Development Co. Ltd.Compositions and methods for treating inflammation
WO2012137202A13 avr. 201211 oct. 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012137207A14 avr. 201211 oct. 2012Ramot At Tel-Aviv University Ltd.Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2012140519A215 avr. 201218 oct. 2012Pluristem Ltd.Methods and systems for harvesting cells
WO2012150600A23 mai 20128 nov. 2012Ramot At Tel-Aviv University Ltd.Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012153333A19 mai 201215 nov. 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A210 mai 201215 nov. 2012Rakuto Bio Technologies Ltd.Methods and device for lightening skin complexion
WO2012156976A116 mai 201222 nov. 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of producing artemisinin in non-host plants and vectors for use in same
WO2012160526A223 mai 201229 nov. 2012Ofir MenasheFormulations of microorganism comprising particles and uses of same
WO2012164380A231 mai 20126 déc. 2012Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
WO2012164565A131 mai 20126 déc. 2012Yeda Research And Development Co. Ltd.Compositions and methods for downregulating prokaryotic genes
WO2012172555A114 juin 201220 déc. 2012Yeda Research And Development Co. Ltd.Combination therapy to prevent dcis formation and progression to breast cancer
WO2012176203A119 juin 201227 déc. 2012Kaiima Bio Agritech Ltd.Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
WO2013011507A117 juil. 201224 janv. 2013Kaiima Bio Agritech Ltd.Maize plants having a partially or fully multiplied genome and uses thereof
WO2013018060A22 août 20127 févr. 2013Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2013021389A29 août 201214 févr. 2013Yeda Research And Development Co.Ltd.Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013024481A113 août 201221 févr. 2013Kaiima Bio Agritech Ltd.Durum wheat plants having a partially or fully multiplied genome and uses thereof
WO2013035071A16 sept. 201214 mars 2013Yeda Research And Development Co. Ltd.Novel risk biomarkers for lung cancer
WO2013035099A16 sept. 201214 mars 2013Yeda Research And Development Co. Ltd.Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013054331A110 oct. 201218 avr. 2013Tel Hashomer Medical Research Infrastructure And Services Ltd.Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013056377A119 oct. 201225 avr. 2013Augurex Life Sciences CorporationAntigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
WO2013061328A225 oct. 20122 mai 2013Yeda Research And Development Co. Ltd.Method of treating cancer
WO2013067076A21 nov. 201210 mai 2013Quark Pharmaceuticals, Inc.Methods and compositions for neuroprotection
WO2013070821A18 nov. 201216 mai 2013Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013076729A122 nov. 201230 mai 2013Danziger Dan Flower FarmOtomeria plants
WO2013076730A127 nov. 201230 mai 2013Yeda Research And Development Co. Ltd.Methods of regulating angiogenesis and compositions capable of same
WO2013084190A16 déc. 201213 juin 2013Yeda Research And Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093921A120 déc. 201227 juin 2013Collplant Ltd.Collagen coated synthetic polymer fibers
WO2013098813A131 déc. 20124 juil. 2013Qbi Enterprises Ltd.Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013098820A126 déc. 20124 juil. 2013Kaiima Bio Agritech Ltd.Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013114363A230 janv. 20138 août 2013Yeda Research And Development Co.Ltd.Antimicrobial agents
WO2013114371A131 janv. 20138 août 2013Protalix Ltd.Dry powder formulations of dnase i
WO2013114373A131 janv. 20138 août 2013Protalix Ltd.Inhalable liquid formulations of dnase i
WO2013114374A131 janv. 20138 août 2013Protalix Ltd.Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013121405A119 févr. 201322 août 2013Protalix Ltd.Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2013121416A15 févr. 201322 août 2013Prolor Biotech Inc.Long-acting coagulation factors and methods of producing same
WO2013121426A113 févr. 201322 août 2013Gamida-Cell Ltd.Culturing of mesenchymal stem cells
WO2013121427A113 févr. 201322 août 2013Gamida-Cell Ltd.Mesenchymal stem cells conditioned medium and methods of generating and using the same
WO2013124816A221 févr. 201329 août 2013Brainstem Biotec Ltd.Generation of neural stem cells and motor neurons
WO2013124817A221 févr. 201329 août 2013Brainstem Biotec Ltd.MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013128454A128 févr. 20136 sept. 2013The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterMale sterile garlic plants, hybrid offspring of same and methods of generating and using same
WO2013132495A17 mars 201312 sept. 2013Yeda Research And Development Co. Ltd.Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A114 mars 201319 sept. 2013Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2013140389A110 mars 201326 sept. 2013Ramot At Tel-Aviv University Ltd.Plif multimeric peptides and uses thereof
WO2013153553A211 avr. 201317 oct. 2013Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2013160895A124 avr. 201331 oct. 2013Biokine Therapeutics Ltd.Peptides and use thereof in the treatment of large cell lung cancer
WO2013168164A19 mai 201314 nov. 2013Yeda Research And Development Co. Ltd.Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013183048A13 juin 201312 déc. 2013Ben-Gurion University Of The Negev Research And Development AuthorityFunctionalized titanium binding peptides and implants coated with same
WO2014006621A13 juil. 20139 janv. 2014Nanospun Technologies Ltd.Methods and devices for adsorption and biodegradation of petroleum
WO2014020599A129 juil. 20136 févr. 2014Yeda Research And Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020608A131 juil. 20136 févr. 2014Yeda Research And Development Co. Ltd.Methods of diagnosing and treating motor neuron diseases
WO2014024183A14 août 201313 févr. 2014Brainstorm Cell Therapeutics Ltd.Methods of generating mesenchymal stem cells which secrete neurotrophic factors
WO2014033723A13 sept. 20136 mars 2014A.B. Seeds Ltd.Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014041544A112 sept. 201320 mars 2014Ramot At Tel-Aviv University Ltd.Immunoparticles and methods of generating and using same
WO2014057490A19 oct. 201317 avr. 2014Ramot At Tel-Aviv University Ltd.Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
WO2014064682A117 oct. 20131 mai 2014Yeda Research And Development Co. Ltd.Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014068553A127 oct. 20138 mai 2014Yeda Research And Development Co. Ltd.Aptamers, multimeric aptamers and uses thereof
WO2014083567A228 nov. 20135 juin 2014Yeda Research And Development Co. Ltd.Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
WO2014106837A230 déc. 201310 juil. 2014A. B. Seeds Ltd.ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
WO2014106838A230 déc. 201310 juil. 2014A.B. Seeds Ltd.Methods of introducing dsrna to plant seeds for modulating gene expression
WO2014108850A29 janv. 201417 juil. 2014Yeda Research And Development Co. Ltd.High throughput transcriptome analysis
WO2014108854A19 janv. 201417 juil. 2014Fusimab Ltd.Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014136113A16 mars 201412 sept. 2014Protalix Ltd.Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014136114A16 mars 201412 sept. 2014Protalix Ltd.TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
WO2014136117A16 mars 201412 sept. 2014Protalix Ltd.USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
WO2014147622A119 mars 201425 sept. 2014Collplant Ltd.Compositions comprising collagen and prp for tissue regeneration
WO2014155376A119 mars 20142 oct. 2014Biokine Therapeutics Ltd.Methods of treating myeloid leukemia
WO2014174470A123 avr. 201430 oct. 2014Yeda Research And Development Co. Ltd.Isolated naive pluripotent stem cells and methods of generating same
WO2014174511A113 avr. 201430 oct. 2014Yeda Research And Development Co. Ltd.Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
WO2014174520A124 avr. 201430 oct. 2014Yeda Research And Development Co. Ltd.Use of inhibitory peptides for the treatment of inflammatory diseases
WO2014188423A121 mai 201427 nov. 2014Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Treatment of mast cell related pathologies
WO2014191995A227 mai 20144 déc. 2014Rakuto Bio Technologies Ltd.Enzymatic system-containing cosmetic compositions
WO2014207744A124 juin 201431 déc. 2014Ramot At Tel-Aviv University Ltd.Omentum based scaffold and delivery system
WO2015015489A128 juil. 20145 févr. 2015Biolinerx Ltd.Antibody for treating diabetes and autoimmune diseases
WO2015033337A12 sept. 201412 mars 2015Technion Research & Development Foundation Limited.A flap for de-novo tissue regeneration
WO2015033343A13 sept. 201412 mars 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for expressing recombinant polypeptides
WO2015033344A14 sept. 201412 mars 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A116 sept. 201419 mars 2015Plexicure Ltd.Isolated proteins capable of binding plexin-a4 and methods of producing and using same
WO2015059690A114 oct. 201430 avr. 2015Yeda Research And Development Co. Ltd.Polynucleotides encoding brex system polypeptides and methods of using s ame
WO2015063768A130 oct. 20147 mai 2015Biokine Therapeutics Ltd.Methods of treating acute myeloid leukemia with a flt3 mutation
WO2015079413A227 nov. 20144 juin 2015Yeda Research And Development Co. Ltd.Synaptojanin-2 inhibitors and uses thereof
WO2015114633A129 janv. 20156 août 2015Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd.Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015114638A23 févr. 20156 août 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of eliminating stem cells
WO2015118537A25 févr. 201513 août 2015Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015118538A15 févr. 201513 août 2015Yeda Research And Development Co. Ltd.Anti cd84 antibodies, compositions comprising same and uses thereof
WO2015118547A19 févr. 201513 août 2015Protalix Ltd.Method of maintaining disease stability in a subject having gaucher's disease
WO2015121859A111 févr. 201520 août 2015Brainstorm Cell Therapeutics Ltd.Method of qualifying cells
WO2015132784A13 mars 201511 sept. 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method and device for detection of pseudomonas aeruginosa
WO2015144874A127 mars 20151 oct. 2015Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Multi-component-multistage malaria vaccines
WO2015159292A214 avr. 201522 oct. 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159293A214 avr. 201522 oct. 2015Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A method and kit for determining the tissue or cell origin of dna
WO2015159295A116 avr. 201522 oct. 2015Yeda Research And Development Co. Ltd.Methods and kits for analyzing dna binding moieties attached to dna
WO2015166492A228 avr. 20155 nov. 2015Yeda Research And Development Co. Ltd.Microbiome response to agents
WO2015170320A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions and methods of using same for controlling pathogenically infected mosquitoes
WO2015170322A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions and methods of using same for increasing resistance of infected mosquitoes
WO2015170323A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions and methods of using same for reducing resistance to mosquito larvicides
WO2015170324A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions for mosquito control and uses of same
WO2015170325A24 mai 201512 nov. 2015Forrest Innovations Ltd.Compositions and methods for reducing pathogen-induced citrus greening
WO2015177800A221 mai 201526 nov. 2015Yeda Research And Development Co. Ltd.Recombinant microorganisms capable of carbon fixation
WO2015186129A12 juin 201510 déc. 2015Technion Research & Development Foundation Limited.Compositions and methods of selectively inhibiting irp1 and treating inflammation
WO2015198320A124 juin 201530 déc. 2015Insight Biopharmaceuticals Ltd.Methods of purifying antibodies
WO2015198334A225 juin 201530 déc. 2015Tel Hashomer Medical Research Infrastructure And Services Ltd.Identification of cancer stem cells and use of same for diagnosis and treatment
WO2016005985A29 juil. 201514 janv. 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method for reprogramming cells
WO2016009436A115 juil. 201521 janv. 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Isolated polypeptides of cd44 and uses thereof
WO2016016894A130 juil. 20154 févr. 2016Yeda Research And Development Co. Ltd.Media for culturing pluripotent stem cells
WO2016030899A127 août 20153 mars 2016Yeda Research And Development Co. Ltd.Methods of treating amyotrophic lateral scleroses
WO2016038609A18 sept. 201517 mars 2016Yeda Research And Development Co. Ltd.Anti-her3 antibodies and uses of same
WO2016038610A18 sept. 201517 mars 2016Yeda Research And Development Co. Ltd.Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016042561A221 sept. 201524 mars 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Downregulating mir-132 for the treatment of lipid related disorders
WO2016079731A217 nov. 201526 mai 2016Yeda Research And Development Co. Ltd.Method of analyzing microbiome
WO2016079736A217 nov. 201526 mai 2016Yeda Research And Development Co. Ltd.Methods of treating diseases related to mitochondrial function
WO2016079739A219 nov. 201526 mai 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
WO2016092555A210 déc. 201516 juin 2016Yeda Research And Development Co. Ltd.Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2016103269A123 déc. 201530 juin 2016Ramot At Tel-Aviv University Ltd.Populations of neural progenitor cells and methods of producing and using same
WO2016108239A130 déc. 20157 juil. 2016Cell Cure Neurosciences Ltd.Rpe cell populations and methods of generating same
WO2016108240A130 déc. 20157 juil. 2016Cell Cure Neurosciences Ltd.Assessing retinal pigment epithelial cell populations
WO2016108244A14 janv. 20167 juil. 2016Protalix Ltd.Modified dnase and uses thereof
WO2016116935A121 janv. 201628 juil. 2016Yeda Research And Development Co. Ltd.Use of rasa2 as a prognostic and therapeutic marker for melanoma
WO2016135732A125 févr. 20161 sept. 2016Yeda Research And Development Co. Ltd.Method of promoting hair growth
WO2016142948A110 mars 201615 sept. 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Decoy oligonucleotides for the treatment of diseases
WO2016147194A117 mars 201622 sept. 2016Yeda Research And Development Co. Ltd.Anti amphiregulin antibodies, compositions comprising same and uses thereof
WO2016157190A131 mars 20166 oct. 2016Yeda Research And Development Co. Ltd.Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
WO2016162870A17 avr. 201613 oct. 2016Ilana NathanCompositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2016174652A130 avr. 20153 nov. 2016Technion Research & Development Foundation LimitedChimeric antigen receptors and methods of their use
WO2016174674A126 avr. 20163 nov. 2016The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterEgr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
WO2016181393A110 mai 201617 nov. 2016Yeda Research And Development Co. Ltd.Citrin inhibitors for the treatment of cancer
WO2016185457A119 oct. 201524 nov. 2016Yeda Research And Development Co. Ltd.Methods of promoting lymphangiogenesis
WO2016185469A117 mai 201624 nov. 2016Yeda Research And Development Co. Ltd.Bacterial populations for promoting health
WO2016185481A219 mai 201624 nov. 2016Yeda Research And Development Co. Ltd.Method of targeting senescent cells
WO2016199140A18 juin 201615 déc. 2016Adicet Bio Inc.T cell receptor like antibodies having fine specificity
WO2016199141A28 juin 201615 déc. 2016Adicet Bio Inc.Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same
WO2016203476A116 juin 201622 déc. 2016Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods and compositions for diagnosing and treating urothelial cancer
WO2016203477A116 juin 201622 déc. 2016Yeda Research And Development Co. Ltd.Conditioning protocols and use of same for tissue regeneration
WO2017009842A214 juil. 201619 janv. 2017Biokine Therapeutics Ltd.Compositions and methods for treating cancer
WO2017009852A114 juil. 201619 janv. 2017Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells
WO2017009853A114 juil. 201619 janv. 2017Yeda Research And Development Co. Ltd.Genetically modified anti-third party central memory t cells and use of same in immunotherapy
WO2017013661A121 juil. 201626 janv. 2017Phytopharma International Ltd.Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
WO2017017686A128 juil. 20162 févr. 2017Hadasit Medical Research Services And Development Ltd.Large scale production of retinal pigment epithelial cells
WO2017021961A12 août 20169 févr. 2017Yeda Research And Development Co. Ltd.Methods of screening for riboswitches and attenuators
WO2017021963A12 août 20169 févr. 2017Biokine Therapeutics Ltd.Cxcr4 binding agents for treatment of diseases
WO2017021972A14 août 20169 févr. 2017Cell Cure Neurosciences Ltd.Preparation of photoreceptors for the treatment of retinal diseases
WO2017021973A14 août 20169 févr. 2017Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017025967A111 août 201616 févr. 2017Forrest Innovations Ltd.Formulations and compositions for delivery of nucleic acids to plant cells
WO2017033188A124 août 20162 mars 2017Yeda Research And Development Co. Ltd.Algal oil and biofuel and methods of producing same
WO2017042814A18 sept. 201616 mars 2017Yeda Research And Development Co. Ltd.Use of perforin positive immature dendritic cells in disease treatment
WO2017072757A125 oct. 20164 mai 2017Yeda Research And Development Co. Ltd.Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2017072763A126 oct. 20164 mai 2017Cell Cure Neurosciences Ltd.Preparation of retinal pigment epithelium cells
WO2017072772A127 oct. 20164 mai 2017Yeda Research And Development Co. Ltd.A method of inducing cardiomyocytes proliferation and treating heart diseases
WO2017072773A127 oct. 20164 mai 2017Ilana NathanCompositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2017077539A13 nov. 201611 mai 2017Ariel-University Research And Development Company Ltd.Compositions for regeneration and repair of neural tissue
WO2017118985A15 janv. 201713 juil. 2017Yeda Research And Development Co. Ltd.Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017130205A131 janv. 20173 août 2017Hadasit Medical Research Services And Development Ltd.Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
WO2017134671A13 févr. 201710 août 2017Yeda Research And Development Co. Ltd.Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
WO2017138007A114 févr. 201717 août 2017Yeda Research And Development Co. Ltd. At The Weizmann Institute Of ScienceMicrobiome-based diagnosis, prediction and treatment of relapsing obesity
WO2017138008A214 févr. 201717 août 2017Yeda Research And Development Co. Ltd.Methods of modulating protein exocytosis and uses of same in therapy
WO2017141253A116 févr. 201724 août 2017Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
WO2017153982A16 mars 201714 sept. 2017Yeda Research And Development Co. Ltd.Method for modulating myelination
WO2017158610A117 mars 201721 sept. 2017Yeda Research And Development Co. Ltd.Methods of isolating barrel-like proteases and identifying peptides processed thereby
Classifications
Classification aux États-Unis435/7.93, 436/808, 435/7.95, 435/188, 436/817, 436/818, 435/971, 436/518, 436/530, 436/531, 435/964, 435/975
Classification internationaleG01N33/543, G01N33/74, G01N33/541
Classification coopérativeY10S435/964, G01N33/743, Y10S436/808, Y10S435/971, Y10S436/818, G01N33/541, Y10S436/817, Y10S435/975
Classification européenneG01N33/541, G01N33/74B